SEARCH
検索詳細
深瀬 直政医学部附属病院 整形外科助教
研究活動情報
■ 受賞- 2022年07月 ON Foundation, AOSSM Orthoregeneration Research Award
- 2021年07月 Steadman Philippon Research Institute, 2021 International Fellowship Basic Science Winner Award
- 2021年04月 ORS ISFR, Young Investigator 3-Minute Thesis (3MT) Competition finalist
- 2017年10月 神戸大学, 第5回神緑会Young Investigator Award (YIA) 優秀賞
- 2017年05月 整形災害外科学研究助成財団, 財団奨励賞
- (一社)中部日本整形外科災害外科学会, 2025年11月, 中部日本整形外科災害外科学会雑誌, 68(6) (6), 844 - 845, 日本語悪性腫瘍切除後の脛骨広範骨欠損に対する新たな生物学的骨再建法:チタンメッシュプレートと自家細片化腸骨移植を用いた1例
- (一社)中部日本整形外科災害外科学会, 2025年11月, 中部日本整形外科災害外科学会雑誌, 68(6) (6), 849 - 850, 日本語悪性腫瘍切除後の脛骨広範骨欠損に対する新たな生物学的骨再建法 チタンメッシュプレートと自家海綿骨を用いた1例
- (一社)中部日本整形外科災害外科学会, 2025年10月, 中部日本整形外科災害外科学会雑誌, 68(秋季学会) (秋季学会), 276 - 276, 日本語下腿に多発したグロムス腫瘍の一例
- Granulocyte-colony stimulating factor (G-CSF) is commonly used to reduce neutropenia-related complications following chemotherapy. It is a glycoprotein that stimulates the production of granulocytes [white blood cells (WBCs) in the bone marrow. In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF. Grade 3 neutropenia occurred on day eight of the fifth chemotherapy cycle, and pegfilgrastim was administered on day nine. A total of 3 days after pegfilgrastim administration, the patient developed a fever that persisted for 6 days. He visited our hospital on day 18 with abdominal pain and elevated WBC count and C-reactive protein levels. Febrile neutropenia was suspected, and antibiotics were administered. However, both blood and urinalysis cultures returned negative results, and antibiotics were ineffective. Contrast-enhanced computed tomography revealed a thickened wall of the brachiocephalic artery and abdominal aorta, consistent with aortitis. After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF.2025年10月, Biomedical reports, 23(4) (4), 161 - 161, 英語, 国際誌研究論文（学術雑誌）
- (公社)日本整形外科学会, 2025年09月, 日本整形外科学会雑誌, 99(8) (8), S1612 - S1612, 日本語
- Epithelioid sarcoma (ES) is a very rare malignant tumor with few effective treatments other than surgical resection. In this study, the efficacy of BNCT for ES was examined using human ES-derived VA-ES-BJ cell-bearing nude mice. Only tumors in the BNCT group injected with p-borono-L-phenylalanine-fructose complex and irradiated with neutrons were destroyed. This study suggests the potential of BNCT as a new option for the treatment of human ES.2025年08月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 222, 111846 - 111846, 英語, 国際誌研究論文（学術雑誌）
- Evidence regarding the effectiveness of rehabilitation treatments in patients with bone metastases remains limited. This study evaluated the implementation and effectiveness of rehabilitation in patients with bone metastases who did not undergo surgery. This retrospective study included 200 patients with nonsurgically treated bone metastases at our institution. The patients were categorized into a rehabilitation group (R group, n = 61) and a non-rehabilitation group (N group, n = 139). Over the course of one month, we compared activities of daily living (ADL), assessed using the Barthel Index (BI), quality of life (QOL), measured using the EuroQoL-5 Dimension (EQ-5D), and demographic and clinical characteristics. Propensity score matching was conducted to minimize selection bias. After matching, 31 patients in each group were included in the analysis. No statistically significant differences were observed in baseline BI and EQ-5D scores between the two groups. In the R group, BI improved significantly from 80 (interquartile range [IQR]: 60-100) to 90 (IQR: 70-100), and EQ-5D improved from 0.444 (IQR: 0.282-0.608) to 0.608 (IQR: 0.533-0.768). In contrast, no improvements were observed in either score in the N group. Chemotherapy was identified as a significant factor associated with improvements in BI (odds ratio 4.03) and EQ-5D (odds ratio 5.29). Rehabilitation may be a valuable treatment option for nonsurgically treated patients with bone metastases, warranting further validation in prospective studies.2025年08月, Journal of bone oncology, 53, 100703 - 100703, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan. METHODS: A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients). RESULTS: The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis. CONCLUSIONS: The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.2025年05月, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 30(3) (3), 523 - 528, 英語, 国内誌研究論文（学術雑誌）
- Myxofibrosarcoma, a rare malignant tumor, predominantly affects the extremities of the elderly. Because of its invasive nature amputation is sometimes required, resulting in serious deterioration of quality of life. Therefore, cell lines established from amputated surgical specimens of myxofibrosarcoma in the upper limbs of elderly patients were used to create a myxofibrosarcoma-bearing animal model and to investigate the therapeutic effect of BNCT thereon. The results demonstrated selective destruction of tumor cells, suggesting the anti-tumor efficacy of BNCT on myxofibrosarcoma.2025年03月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 217, 111603 - 111603, 英語, 国際誌研究論文（学術雑誌）
- Cancer stem cells (CSCs) have been implicated as critical mediators in the progression, chemoresistance and metastatic capabilities of diverse malignancies, including osteosarcoma (OS). The authors have succeeded in generating CSC‑like cells (MG‑OKS) from the OS cell line MG‑63 by transducing defined factors. A significant increase in small proline‑rich protein 1A (SPRR1A) expression, a cross‑linked envelope protein in keratinocytes, was observed in MG‑OKS cells. Therefore, SPRR1A could be involved in tumor initiation, growth and poor OS progression. However, its specific role in OS remains unclear. The present study aimed to evaluate the role of SPRR1A in OS both in vitro and in vivo using MG‑OKS cells. Three experimental groups were established: MG‑OKS cells transfected with SPRR1A small interfering (si)RNA (siMG‑OKS), untransfected MG‑OKS cells and MG‑OKS cells transfected with scrambled siRNA (scMG‑OKS) as controls. SPRR1A expression, morphological changes, cell proliferation and migration were assessed in these groups. RNA sequencing was performed to examine the genetic changes caused by SPRR1A suppression. To evaluate tumorigenicity in vivo, cells from each group were subcutaneously transplanted into the backs of nude mice. Tumor volume and Ki‑67 expression were assessed and compared among the three groups at four weeks post‑transplantation. The siMG‑OKS group exhibited altered cell morphology, reduced cell proliferation and decreased migratory abilities in vitro. RNA sequencing revealed suppression of genes involved in cell adhesion in the siMG‑OKS group. Furthermore, the in vivo tumorigenicity of siMG‑OKS was lower than that of the other two experimental groups. These findings suggest that SPRR1A is one of the key cell adhesion‑related molecules involved in OS progression, potentially serving as a therapeutic target for this refractory tumor. However, further research is needed to fully elucidate the mechanisms by which SPRR1A influences OS pathogenesis and to explore its clinical potential.2025年02月, Oncology reports, 53(2) (2), 英語, 国際誌研究論文（学術雑誌）
- (NPO)日本緩和医療学会, 2025年, Palliative Care Research, 20(Suppl._Kansai) (Suppl._Kansai), S701 - S701, 日本語がん骨転移チーム医療を学ぶ～自施設にリソースがない時の対応策～ 四肢長管骨・骨盤の骨転移への実践的アプローチ
- BACKGROUND: Microfracture is one surgical treatment strategy for osteochondral lesions of the talus (OLTs) but results in fibrocartilage repair tissue, which has inferior mechanical properties to native hyaline cartilage. Biological regulation of microfracture has been suggested to improve the quality of cartilage repair in patients. PURPOSE: To determine if administration of losartan, fisetin, or losartan and fisetin combined can enhance microfracture-mediated cartilage repair of OLTs in a rabbit model. STUDY DESIGN: Controlled laboratory study. METHODS: Four-month-old female rabbits were divided into the following groups (8 rabbits per group): microfracture only (microfracture), microfracture plus losartan (losartan), microfracture plus fisetin (fisetin), and microfracture plus losartan and fisetin (losartan+fisetin). A 2.7-mm osteochondral defect and 4 microfracture holes were created in the talar dome cartilage. The rabbits were administered losartan (10 mg/kg/day), fisetin (20 mg/kg/day), or losartan and fisetin orally until euthanized 12 weeks after surgery. Gross evaluation, micro-computed tomography, histology, and immunohistochemistry evaluations of the osteochondral defects were performed as well as quantitative polymerase chain reaction of capsule tissue and enzyme-linked immunosorbent assay of serum. RESULTS: The losartan and fisetin groups had increased International Cartilage Regeneration & Joint Preservation Society macroscopic scores with improved cartilage repair and enhanced subchondral bone healing compared with the microfracture group. However, the losartan+fisetin group did not show a synergistic effect. O'Driscoll histology scores were higher in the losartan and fisetin groups compared with the microfracture group, while the losartan+fisetin group had a lower score than the losartan, fisetin, and microfracture groups. Collagen type 2 staining revealed organized chondrocytes in the losartan and fisetin groups, but the losartan+fisetin group did not show improvement when compared with other groups. Fisetin treatment decreased catalase and transforming growth factor-β1-activated kinase 1 expression in capsular tissue. CONCLUSION: Concomitant microfracture and biological regulation, using oral administration of either losartan or fisetin, may improve cartilage healing of OLTs; however, losartan and fisetin combined in the current drug administration regimen does not appear to provide synergistic effects. CLINICAL RELEVANCE: Oral intake of losartan or fisetin may result in beneficial effects on microfracture-mediated cartilage repair of OLTs.2024年12月, The American journal of sports medicine, 52(14) (14), 3625 - 3640, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/OBJECTIVES: Long-standing groin pain is a severe issue for athletes, often associated with the cleft sign on magnetic resonance imaging (MRI) scans, yet its underlying causes are poorly understood. The purpose of this study is to histologically examine the pubic plate structure in cadavers with and without the cleft sign on MRI, shedding light on the pathology behind the cleft sign. METHODS: Three fresh human pelvic cadavers underwent 3.0T MRI to detect the cleft sign before histological dissection of pubic plates. Pubic plate tissues were fixed in formalin, decalcified, and processed. Of the two cleft sign-negative specimens, one was cut into sagittal sections, and the other was cut into coronal sections for histology. For the cleft sign positive specimen, a sagittal section was cut. Moreover, 5 µm thick sections were cut at different axial levels for each orientation. Sections were subjected to Safranin O, Alcian blue, and Herovici's staining or hematoxylin and eosin staining. RESULTS: MRI confirmed that one specimen had a cleft sign in the inferior region on both sides of the pubis and that two specimens had no cleft sign. Both sagittal and coronal sections showed the presence of a cartilage structure continuing from the pubic symphysis to 3 mm laterally within the pubic plate. In the specimen with a positive cleft sign, cartilage damage within the pubic symphysis and pubic plate was identified as revealed by Safranin O staining, Herovici's staining, and H&E staining. CONCLUSIONS: This study elucidated the existence of a cartilage component extending from the pubic symphysis to the pubic plate. The cleft sign in MRI correlated with a disruption in the cartilage component in histology within this specific area.2024年09月, Diagnostics (Basel, Switzerland), 14(18) (18), 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Bone fracture is one of the most globally prevalent injuries, with an estimated 189 million bone fractures occurring annually. Delayed union or nonunion occurs in up to 15% of fractures and involves the interruption or complete failure of bone continuity following fracture. Preclinical testing is essential to support the translation of novel strategies to promote improved fracture repair treatment, but there is a paucity of small animal models that recapitulate clinical attributes associated with delayed fracture healing. This study explores whether the Zmpste24 -/- (Z24 -/- ) knockout mouse model of Hutchinson-Gilford progeria syndrome presents with delayed fracture healing. Leveraging the previously characterized Z24 -/- phenotype of genomic instability, epigenetic changes, and fragility, we hypothesize that these underlying alterations will lead to significantly delayed fracture healing relative to age-matched wild type (WT) controls. METHODS: WT and Z24 -/- mice received intramedullary fixed tibia fractures at ∼12 weeks of age. Mice were sacrificed throughout the time course of repair for the collection of organs that would provide information regarding the local (fracture callus, bone marrow, inguinal lymph nodes) versus peripheral (peripheral blood, contralateral tibia, abdominal organs) tissue microenvironments. Analyses of these specimens include histomorphometry, μCT, mechanical strength testing, protein quantification, gene expression analysis, flow cytometry for cellular senescence, and immunophenotyping. RESULTS: Z24 -/- mice demonstrated a significantly delayed rate of healing compared to WT mice with consistently smaller fracture calli containing higher proportion of cartilage and less bone after injury. Cellular senescence and pro-inflammatory cytokines were elevated in the Z24 -/- mice before and after fracture. These mice further presented with a dysregulated immune system, exhibiting generally decreased lymphopoiesis and increased myelopoiesis locally in the bone marrow, with more naïve and less memory T cell but greater myeloid activation systemically in the peripheral blood. Surprisingly, the ipsilateral lymph nodes had increased T cell activation and other pro-inflammatory NK and myeloid cells, suggesting that elevated myeloid abundance and activation contributes to an injury-specific hyperactivation of T cells. CONCLUSION: Taken together, these data establish the Z24 -/- progeria mouse as a model of delayed fracture healing that exhibits decreased bone in the fracture callus, with weaker overall bone quality, immune dysregulation, and increased cellular senescence. Based on this mechanism for delayed healing, we propose this Z24 -/- progeria mouse model could be useful in testing novel therapeutics that could address delayed healing. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: This study employs a novel animal model for delayed fracture healing that researchers can use to screen fracture healing therapeutics to address the globally prevalent issue of aberrant fracture healing.2024年05月, bioRxiv : the preprint server for biology, 英語, 国際誌研究論文（学術雑誌）
- Background and Objectives: Changes in activities of daily living (ADL) and quality of life (QOL) of patients with bone metastasis who underwent surgical treatment through Bone Metastasis Cancer Boards (BMCBs), a recent multidisciplinary approach for managing bone metastases, have been reported; however, no reports exist on patients who undergo conservative treatment. In this study, we aimed to evaluate these patients' ADL and QOL and examine the factors influencing changes in these parameters. Materials and Methods: We retrospectively reviewed 200 patients with bone metastases who underwent conservative therapy through BMCBs between 2013 and 2021. A reassessment was conducted within 2-8 weeks after the initial assessment. Patients' background and changes in performance status (PS), Barthel Index (BI), EuroQol five-dimension (EQ-5D) scores, and Numerical Rating Scale (NRS) scores were initially assessed. Furthermore, we categorized patients into two groups based on improvements or deteriorations in ADL and QOL and performed comparative analyses. Results: Significant improvements in EQ-5D (0.57 ± 0.02 versus [vs.] 0.64 ± 0.02), NRS max (5.21 ± 0.24 vs. 3.56 ± 0.21), and NRS average (2.98 ± 0.18 vs. 1.85 ± 0.13) scores were observed between the initial assessment and reassessment (all p < 0.001). PS (1.84 ± 0.08 vs. 1.72 ± 0.08) and BI (83.15 ± 1.68 vs. 84.42 ± 1.73) also showed improvements (p = 0.06, and 0.054, respectively). In addition, spinal cord paralysis (odds ratio [OR]: 3.69, p = 0.049; OR: 8.42, p < 0.001), chemotherapy (OR: 0.43, p = 0.02; OR: 0.25, p = 0.007), and NRS average scores (OR: 0.38, p = 0.02; OR: 0.14, p < 0.001) were independent factors associated with ADL and QOL. Conclusions: Patients with bone metastases who underwent conservative treatment through BMCBs exhibited an increase in QOL without a decline in ADL. The presence of spinal cord paralysis, absence of chemotherapy, and poor pain control were associated with a higher risk of deterioration in ADL and QOL.2024年05月, Medicina (Kaunas, Lithuania), 60(6) (6), 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: To evaluate symptom duration and its relationship to patient-reported outcomes (PROs) and survivorship after hip arthroscopy in adolescents. METHODS: Patients ≤18 at time of primary hip arthroscopy for femoroacetabular impingement (FAI) between January 2011 and September 2018 were included. Exclusion criteria consisted of history of previous ipsilateral hip surgery, presence of osteoarthritis or dysplasia on preoperative radiographs, previous hip fracture, or history of slipped capital femoral epiphysis or Legg-Calve-Perthes disease. Minimum 2-year PROs (modified Harris Hip Score, Hip Outcome Score [HOS]-Activities of Daily Living, HOS-Sport Scale, Short Forms 12 [SF-12]), minimum clinically significant difference (MCID) and patient-acceptable symptom state (PASS) rates, and revision surgery rates were compared based on symptom duration. RESULTS: Two-year minimal follow-up was obtained for 111 patients (134 hips) (80%), including 74 females and 37 males with a mean age of 16.4 ± 1.1 (range 13.0-18.0). The mean symptom duration was 17.2 ± 15.2 months (range 43 days to 6.0 years). Ten patients (11 hips), 6 females (7 hips) and 4 males, required revision surgery at an average of 2.3 ± 1.0 years (range 0.9-4.3 years). At a mean follow-up of 4.8 ± 2.2 years (range 2-10 years), there were statistically significant improvements in all PROs (P < .05 for all). Symptom duration showed no significant correlation to post-operative scores (correlation coefficient range -0.162 to -0.078, P > .05 for all). Symptom duration ≤12 months versus >12 months or as a continuous variable was not a predictor for requiring revision surgery or achieving MCID/PASS (95% confidence interval crosses 1 for all). CONCLUSIONS: In an adolescent cohort of symptomatic FAI patients who underwent hip arthroscopy, there is no difference in PRO measures when analyzing symptom duration by arbitrary time intervals or as a continuous variable. LEVEL OF EVIDENCE: Level IV, case series.2023年12月, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 39(12) (12), 2466 - 2473, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: To investigate the effects of combining bone marrow stimulation (BMS) with oral losartan to block transforming growth factor β1 (TGF-β1) on biomechanical repair strength in a rabbit chronic injury model. METHODS: Forty rabbits were randomly allocated into 4 groups (10 in each group). The supraspinatus tendon was detached and left alone for 6 weeks to establish a rabbit chronic injury model and was then repaired in a surgical procedure using a transosseous, linked, crossing repair construct. The animals were divided into the following groups: control group (group C), surgical repair only; BMS group (group B), surgical repair with BMS of the tuberosity; losartan group (group L), surgical repair plus oral losartan (TGF-β1 blocker) for 8 weeks; and BMS-plus-losartan group (group BL), surgical repair plus BMS plus oral losartan for 8 weeks. At 8 weeks after repair, biomechanical and histologic evaluations were performed. RESULTS: The biomechanical testing results showed significantly higher ultimate load to failure in group BL than in group B (P = .029) but not compared with group C or group L. A 2 × 2 analysis-of-variance model found that the effect of losartan on ultimate load significantly depended on whether BMS was performed (interaction term F1,28 = 5.78, P = .018). No difference was found between the other groups. No difference in stiffness was found between any groups. On histologic assessment, groups B, L, and BL showed improved tendon morphology and an organized type I collagen matrix with less type III collagen compared with group C. Group BL showed the most highly organized tendon matrix with more type I collagen and less type III collagen, which indicates less fibrosis. Similar results were found at the bone-tendon interface. CONCLUSIONS: Rotator cuff repair combined with oral losartan and BMS of the greater tuberosity showed improved pullout strength and a highly organized tendon matrix in this rabbit chronic injury model. CLINICAL RELEVANCE: Tendon healing or scarring is accompanied by the formation of fibrosis, which has been shown to result in compromised biomechanical properties, and is therefore a potential limiting factor in healing after rotator cuff repair. TGF-β1 expression has been shown to play an important role in the formation of fibrosis. Recent studies focusing on muscle healing and cartilage repair have found that the downregulation of TGF-β1 by losartan intake can reduce fibrosis and improve tissue regeneration in animal models.2023年12月, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 39(12) (12), 2408 - 2419, 英語, 国際誌研究論文（学術雑誌）
- INTRODUCTION: The introduction of tyrosine kinase inhibitors has revolutionized treatment strategies for metastatic renal cell carcinoma (RCC) and has improved survival rates. The number of patients with bone metastases from RCC requiring surgery will increase as survival rates improve. However, there is insufficient evidence to standardize the treatment of bone metastases after the introduction of targeted therapy for metastatic RCC. We aimed to determine the outcomes of palliative surgical treatment of bone metastases in the extremities of patients with metastatic RCC. MATERIALS AND METHODS: We retrospectively reviewed 26 lesions from 17 patients who underwent surgery for extremity and acetabular bone metastases and were treated with targeted therapies for advanced RCC between 2008 and 2020. The median follow-up duration was 19 months (range, 4-76). We assessed the patients' activities of daily living, quality of life, and pain and analyzed their postoperative values relative to preoperative values. Postoperative overall survival (OS), local progression-free survival (LPFS), and the factors affecting them were evaluated using the Kaplan-Meier method and log-rank test. RESULTS: The 5-year OS and LPFS rates were 39.5% and 65.6%, respectively. The factors affecting OS were sex, Katagiri score, visceral metastases, and preoperative targeted therapy, while the factors affecting LPFS were pathologic fractures and surgical technique. CONCLUSION: In this study, the postoperative outcomes of palliative surgery for bone metastases from metastatic RCC were good. We suggest that systemic treatment should be prioritized over local control for advanced bone metastasis in RCC and surgery before pathological fracture should be performed for local control.2023年05月, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 49(5) (5), 928 - 933, 英語, 国際誌研究論文（学術雑誌）
- Rotator cuff tears are a common soft tissue injury that can significantly decrease function of the shoulder and cause severe pain. Despite progress in surgical technique, rotator cuff repairs (RCRs) do not always heal efficiently. Many failures occur at the bone-tendon interface as a result of poor healing capacity of the tendon and failure to regenerate the native histological anatomy of the enthesis. While allografts are commercially available, clinical use is limited as they do not stimulate tissue regeneration and are associated with a structural failure of up to 40% in re-tear cases. Novel tissue engineering strategies are being developed with promise, but most involve addition of cells and/or growth factors which extends the timeline for clinical translation. Thus, there exists a significant unmet clinical need for easily translatable surgical augmentation approaches that can improve healing in RCR. Here we describe the development of a decellularized tendon matrix (DTM) putty that preserves native tendon bioactivity using a novel processing technique. In vitro, DTM promoted proliferation of tenocytes and adipose-derived stem cells with an increase in expression-specific transcription factors seen during enthesis development, Scleraxis and Sox9. When placed in a rabbit model of a chronic rotator cuff tear, DTM improved histological tissue repair by promoting calcification at the bone-tendon interface more similar to the normal fibrocartilaginous enthesis. Taken together, these data indicate that the engineered DTM putty retains a pro-regenerative bioactivity that presents a promising translational strategy for improving healing at the enthesis.2023年, Journal of tissue engineering and regenerative medicine, 2023, 4665795 - 4665795, 英語, 国際誌研究論文（学術雑誌）
- Ewing sarcoma (ES) is an aggressive primary malignant bone tumor that predominantly affects children and young adults. Multimodal treatment approaches have markedly improved the survival of patients with localized ES. However, local recurrence and distant metastasis following curative therapies remain a main concern for patients with ES. Recent studies have suggested that slow‑cycling cells (SCCs) are associated with tumor progression, local recurrence and distant metastasis in various types of cancers. According to the results of these studies, it was hypothesized that SCCs may play a critical role in tumor progression, chemoresistance and local/distal recurrence in patients with ES. The present study applied a label‑retaining system using carboxyfluorescein diacetate succinimidyl ester (CFSE) to identify and isolate SCCs in ES cell lines. In addition, the properties of SCCs, including sphere formation ability, cell cycle distribution and chemoresistance, in comparison with non‑SCCs were investigated. RNA sequencing also revealed several upregulated genes in SCCs as compared with non‑SCCs; the identified genes not only inhibited cell cycle progression, but also promoted the malignant properties of SCCs. On the whole, the present study successfully identified SCCs in ES cells through a label‑retaining system using CFSE. Moreover, to the best of our knowledge, the present study is the first to describe the characteristic properties of SCCs in ES. The findings of this study, if confirmed, may prove to be useful in elucidating the underlying molecular mechanisms and identifying effective therapeutic targets for ES.2022年11月, International journal of oncology, 61(5) (5), 英語, 国際誌研究論文（学術雑誌）
- There is an unmet need for improved, clinically relevant methods to longitudinally quantify bone healing during fracture care. Here we develop a smart bone plate to wirelessly monitor healing utilizing electrical impedance spectroscopy (EIS) to provide real-time data on tissue composition within the fracture callus. To validate our technology, we created a 1-mm rabbit tibial defect and fixed the bone with a standard veterinary plate modified with a custom-designed housing that included two impedance sensors capable of wireless transmission. Impedance magnitude and phase measurements were transmitted every 48 h for up to 10 weeks. Bone healing was assessed by X-ray, µCT, and histology. Our results indicated the sensors successfully incorporated into the fracture callus and did not impede repair. Electrical impedance, resistance, and reactance increased steadily from weeks 3 to 7-corresponding to the transition from hematoma to cartilage to bone within the fracture gap-then plateaued as the bone began to consolidate. These three electrical readings significantly correlated with traditional measurements of bone healing and successfully distinguished between union and not-healed fractures, with the strongest relationship found with impedance magnitude. These results suggest that our EIS smart bone plate can provide continuous and highly sensitive quantitative tissue measurements throughout the course of fracture healing to better guide personalized clinical care.2022年08月, Sensors (Basel, Switzerland), 22(16) (16), 英語, 国際誌研究論文（学術雑誌）
- This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.2022年06月, Cancers, 14(12) (12), 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: The most reliable suture technique for capsular closure after a capsulotomy remains unknown. PURPOSE: To determine which suture technique best restores native stability after a 5-cm interportal capsulotomy. STUDY DESIGN: Controlled laboratory study. METHODS: Ten human cadaveric hip specimens were tested using a 6-degrees-of-freedom robotic arm in 7 states: intact, capsular laxity, 5-cm capsulotomy, standard suture, shoelace, double shoelace, and Quebec City slider (QCS). Rotational range of motion (ROM) was measured across 9 tests: flexion, extension, abduction, abduction at 45° of flexion, adduction, external rotation, internal rotation, anterior impingement, and log roll. Distraction (ie, femoral head translation [FHT]) was measured across a range of flexion and abduction angles. RESULTS: When compared with the native state, the 5-cm capsulotomy state showed the largest laxity increases on all tests, specifically in external rotation ROM (+13.4°), extension ROM (+11.5°), and distraction FHT (+4.5 mm) (P < .001 for all). The standard suture technique was not significantly different from the 5-cm capsulotomy on any test and demonstrated significantly more flexion ROM than the double shoelace suture (+1.41°; P = .049) and more extension ROM (+5.51°; P = .014) and external rotation ROM (+6.03°; P = .021) than the QCS. The standard suture also resulted in significantly higher distraction FHT as compared with the shoelace suture (+1.0 mm; P = .005), double shoelace suture (+1.4 mm; P < .001), and QCS (+1.1 mm; P = .003). The shoelace, double shoelace, and QCS techniques significantly reduced hip laxity when compared with the 5-cm capsulotomy state, specifically in external rotation ROM (respectively, -8.1°, -7.8°, and -10.2°), extension ROM (-6.3°, -7.3°, and -8.1°), and distraction FHT (-1.8, -2.2, and -1.9 mm) (P ≤ .003 for all). These 3 techniques restored native stability (no significant difference from intact) on some but not all tests, and no significant differences were observed among them on any test. CONCLUSION: Hip capsule closure with the standard suture technique did not prevent postoperative hip instability after a 5-cm capsulotomy, and 3 suture techniques were found to be preferable; however, none perfectly restored native stability at time zero. CLINICAL RELEVANCE: The shoelace, double shoelace, and QCS suture techniques are recommended when closing the hip capsule.2022年06月, Orthopaedic journal of sports medicine, 10(6) (6), 23259671221089946 - 23259671221089946, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Because of the unique theoretical surgical risks, including osteonecrosis, acute iatrogenic slipped capital femoral epiphysis, and epiphyseal injury, the optimal treatment strategy for femoroacetabular impingement (FAI) in growing adolescents has yet to be established. The aim of this study was to compare the clinical outcomes of primary arthroscopic treatment of FAI in growing adolescents with a matched adult group. METHODS: Patients with FAI who underwent arthroscopic treatment with a minimum follow-up of 2 years were included. Patients with previous ipsilateral hip surgery, an Outerbridge grade of ≥3, a preoperative Tönnis grade of ≥2, or evidence of dysplasia (lateral center-edge angle of <25°) were excluded. Eligible patients who were ≤19 years old and whose proximal femoral physis had not yet closed were matched to adult (20 to 40-year-old) counterparts in a 1:1 ratio by sex, body mass index, and time of surgery. For the adolescents, cam resection was performed with a physeal-sparing approach. Outcome scores, including the modified Harris hip score (mHHS), Hip Outcome Score-Activities of Daily Living (HOS-ADL), and HOS-Sports-Specific Subscale (HOS-SSS), were prospectively collected. RESULTS: Of the 196 eligible adolescents, 157 (80%) were pair-matched to adult controls, with a median postoperative follow-up of 8.9 and 6.6 years, respectively. Fourteen (9%) of the adolescents required revision hip arthroscopy compared with 18 adults (11%) (p = 0.46). No patient in the adolescent group had conversion to a total hip arthroplasty (THA), while 3 in the adult group had a THA (p = 0.25). For adolescents without subsequent hip surgery, the median mHHS improved from 59 preoperatively to 96 postoperatively; the HOS-ADL, from 71 to 98; and the HOS-SSS, from 44 to 94 (p < 0.001), which were significantly higher postoperative scores than those of the matched adults (p < 0.05) despite similar or inferior baseline scores. No complications were found during the office visit or at the final follow-up. CONCLUSIONS: Hip arthroscopy performed with a physeal-sparing approach for FAI in growing adolescents is safe and effective and yields superior clinical outcomes compared with those in a matched adult group. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.2022年05月, The Journal of bone and joint surgery. American volume, 104(10) (10), 902 - 909, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Within the hip joint, the anatomy of the acetabulum and cotyloid fossa is well established. There is little literature describing the association between the size of the cotyloid fossa relative to the acetabulum and characteristics of patients with femoroacetabular impingement (FAI). PURPOSE/HYPOTHESIS: The purpose was to calculate the cotyloid fossa coverage percentage in the acetabulum and determine its association with patient characteristics, radiographic parameters, intra-articular findings, and preoperative patient-reported outcomes in patients with FAI. We hypothesized there is an association between the cotyloid fossa coverage percentage of the acetabulum and characteristics of patients with FAI. STUDY DESIGN: Cross-sectional study; Level of evidence, 3. METHODS: Patients were included who underwent standard clinical 3-T magnetic resonance imaging of the hip and primary arthroscopic FAI correction surgery during 2015 and 2016. Exclusion criteria were age <18 or >40 years, osteoarthritis, labral reconstruction, previous ipsilateral hip surgery, and hip dysplasia. Measurements of the cotyloid fossa and surrounding lunate cartilage were performed to calculate cotyloid fossa width (CFW) and cotyloid fossa height (CFH) coverage percentages. The relationships between coverage percentages and patient characteristics and intraoperative findings were assessed using independent t tests or Pearson correlations. RESULTS: An overall 146 patients were included. Alpha angle negatively correlated with CFH coverage percentage (r = -0.19; P = .03) and positively correlated with labral tear size (r = 0.28; P < .01). CFH coverage percentage was negatively correlated with labral tear size (r = -0.24; P < .01). Among patients with degenerative tears, CFH was negatively correlated with labral tear size (r = -0.31; P < .01). However, this association was no longer significant after adjusting for sex (partial r = -0.10; P = .39). Cotyloid fossa coverage was not associated with the condition of the cotyloid fossa synovium (synovitis vs no synovitis). CFW coverage percentage was negatively correlated with the 12-Item Short Form Health Survey (SF-12) physical component summary score (r = -0.23; P < .01). CONCLUSION: The CFW and CFH coverage percentages may be associated with alpha angle, labral tear size, and SF-12 physical component summary score in patients with FAI. We may be able to predict the labral condition based on preoperative measurements of CFH and CFW coverage percentages.2022年01月, The American journal of sports medicine, 50(1) (1), 50 - 57, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: Soft tissue sarcomas (STSs) constitute a group of rare, heterogeneous tumors representing approximately 1% of all cancers. Owing to the rarity and pathological diversity of the disease, unplanned excision (UE) has often been performed for STS, resulting in an unfavorable prognosis. This study aimed to clarify clinical outcomes and prognostic factors in STS patients who underwent UE. PATIENTS AND METHODS: In a retrospective review of the medical records of patients with STS who underwent surgery at our institution between 1999 and 2015, patients were enrolled to either a UE group or a planned excision (PE) group. An analysis was then conducted to identify factors associated with prognosis after UE. RESULTS: Of 134 patients undergoing surgery for STS, 110 were enrolled to the PE group and 24 to the UE group. The median size of the primary tumor was significantly smaller, and more lesions were located in the superficial layer in the UE group than in the PE group. In addition, plastic reconstruction after additional radical resection was required significantly more often in the UE group than in the PE group. No significant difference in overall survival, local recurrence-free survival, or disease-free survival (DFS) between the UE and PE groups was observed; however, metastasis-free survival was significantly better in the UE group. In the UE group, poorer DFS was associated with older age (≥61 years) and a larger primary tumor (≥2.9 cm). CONCLUSION: A prognosis similar to that in patients undergoing PE could be achieved by appropriate additional surgeries in patients initially undergoing UE. However, UE for STS should be avoided, especially in older patients and those with a larger primary tumor.2022年, Cancer management and research, 14, 1815 - 1824, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Based on previous studies, it is difficult to discern whether patients who have femoroacetabular impingement (FAI) with borderline developmental dysplasia of the hip (BDDH) would benefit from arthroscopy when compared with patients without BDDH. PURPOSE: To evaluate the existing comparative literature on arthroscopic findings, procedures, patient-reported outcomes (PROs), and failures in patients who have FAI with BDDH compared with those without BDDH. STUDY DESIGN: Systematic review; Level of evidence, 3. METHODS: The PubMed, Embase, and Ovid databases were searched for studies published up to August 31, 2019, that reported outcomes after arthroscopy to treat patients who had FAI with BDDH. Included studies were required to have patients diagnosed with FAI and BDDH who were treated arthroscopically and compared with control patients (FAI without BDDH). Arthroscopic findings, PROs, and revision or total hip arthroplasty (THA) conversion rates were compared between groups. RESULTS: Included in the review were 4 articles (933 patients). Patients who had FAI with BDDH were defined as having a lateral center-edge angle (LCEA) of either 18° to 25° or 20° to 25°; for control patients, the maximum LCEA was 40°. Across the studies, there were 224 patients who had FAI with BDDH compared with 709 control patients; the mean follow-up time ranged from 21.6 to 31.3 months among the groups. Improvements were shown across all PROs in each study. Random-effects meta-analysis indicated no statistically significant differences in postoperative PROs, the risk for revision surgery, or conversion to THA between the patients who had FAI with versus without BDDH. CONCLUSION: The results of the current review indicated that hip arthroscopy produced similar short-term outcomes between patients who had FAI with versus without BDDH.2021年08月, Orthopaedic journal of sports medicine, 9(8) (8), 23259671211015973 - 23259671211015973, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: The treatment for borderline developmental dysplasia of the hip (BDDH) has historically been arthroscopic surgery or periacetabular osteotomy (PAO). As orthopaedic surgery is constantly evolving, a lack of comparison of outcomes for these 2 treatment methods could potentially be stalling the progression of treatment for patients with BDDH. PURPOSE: To evaluate the existing literature on patient characteristics, procedures, clinical outcomes, and failure rates for patients with BDDH and to determine whether PAO or hip arthroscopic surgery is a better treatment method for patients with BDDH. STUDY DESIGN: Systematic review; Level of evidence, 4. METHODS: Studies included were found using the following search words: "hip" and "borderline dysplasia," "osteotomy" or "arthroscopy," and "outcome" or "procedure." Articles were included if they detailed participants of all sexes and ages, reported on isolated hips, and had patients diagnosed with BDDH. RESULTS: A search was conducted across 3 databases, resulting in 469 articles for consideration, from which 12 total studies (10 on arthroscopic surgery and 2 on PAO) were chosen for a review. There were 6 studies that included patients with a lateral center-edge angle of 18° to 25°, while the remainder included patients with a lateral center-edge angle of 20° to 25°. All the studies reviewing arthroscopic surgery reported concomitant/accessory procedures, while the articles on the topic of PAO did not. It was determined that, whether treated using arthroscopic surgery or PAO, outcomes improved across all patient-reported outcome measures. Revision surgery was also common in both procedures. CONCLUSION: There is a lack of consensus in the literature on the best treatment option for patients with BDDH. Preoperative patient characteristics and concomitant injuries should be considered when evaluating which surgical procedure will result in the most favorable outcomes.2021年05月, Orthopaedic journal of sports medicine, 9(5) (5), 23259671211007401 - 23259671211007401, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Skeletal related events due to metastatic bone tumors markedly affect the activities of daily living (ADL) and quality of life (QOL) in cancer patients. We focused on multidisciplinary therapy for metastatic bone tumors. This study aimed to evaluate the outcomes of surgical treatment for metastatic bone tumors in the extremities. METHODS: We retrospectively reviewed 114 patients who underwent surgical treatment for metastatic bone tumors of the extremities between 2008 and 2019 and 69 patients were reassessed for more than 6 months after surgery. The most common primary tumor was renal, followed by lung, thyroid, and breast cancers. We assessed 69 patients' performance status (PS), Barthel Index (BI) for ADL, EuroQol 5 Dimensions (EQ-5D) for QOL, and numerical rating scale (NRS) for pain and analyzed these postoperative values relative to preoperative values using Friedman's test. The postoperative overall survival and the prognostic factors were evaluated using the Kaplan-Meier method, the log-rank test and Cox proportional hazards analysis. RESULTS: The 1-year overall survival rate was 59%, and the median survival time after surgery was 20 months. Primary tumor, visceral metastasis, and surgical procedure were risk factors correlated with overall survival. PS, BI, EQ-5D, and NRS improved at 3 months after surgery and these improvements were maintained for 6 months after surgery regardless of the surgical procedure. CONCLUSIONS: The significant factors affecting survival after surgical treatment for bone metastases included the primary tumor, presence of visceral metastases, and internal fixation without tumor resection or curettage. Surgical treatment for metastatic bone tumors effectively reduced pain and improved PS, ADL, and QOL postoperatively after 3 months.2021年04月, Journal of bone oncology, 27, 100352 - 100352, 英語, 国際誌研究論文（学術雑誌）
- Synovial sarcoma is a rare tumor requiring new treatment methods. A 46-year-old woman with primary monophasic synovial sarcoma in the left thigh involving the sciatic nerve, declining surgery because of potential dysfunction of the affected limbs, received two courses of BNCT. The tumor thus reduced was completely resected with no subsequent recurrence. The patient is now able to walk unassisted, and no local recurrence has been observed, demonstrating the applicability of BNCT as adjuvant therapy for synovial sarcoma. Further study and analysis with more experience accumulation are needed to confirm the real impact of BNCT efficacy for its application to synovial sarcoma.2021年03月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 169, 109407 - 109407, 英語, 国際誌研究論文（学術雑誌）
- Traditional Anterior Cruciate Ligament (ACL) reconstruction is commonly performed using an allograft or autograft and possesses limitations such as donor site morbidity, decreased range of motion, and potential infection. However, a biodegradable synthetic graft could greatly assist in the prevention of such restrictions after ACL reconstruction. In this study, artificial grafts were generated using "wet" and "dry" electrospinning processes with a biodegradable elastomer, poly (ester urethane) urea (PEUU), and were evaluated in vitro and in vivo in a rat model. Four groups were established: (1) Wet PEUU artificial ligament, (2) Dry PEUU artificial ligament, (3) Dry polycaprolactone artificial ligament (PCL), and (4) autologous flexor digitorum longus tendon graft. Eight weeks after surgery, the in vivo tensile strength of wet PEUU ligaments had significantly increased compared to the other synthetic ligaments. These results aligned with increased infiltration of host cells and decreased inflammation within the wet PEUU grafts. In contrast, very little cellular infiltration was observed in PCL and dry PEUU grafts. Micro-computed tomography analysis performed at 4 and 8 weeks postoperatively revealed significantly smaller bone tunnels in the tendon autograft and wet PEUU groups. The Wet PEUU grafts served as an adequate functioning material and allowed for the creation of tissues that closely resembled the ACL.2021年02月, Acta biomaterialia, 121, 275 - 287, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: This study aimed to evaluate the association of clinical characteristics with treatment outcomes to ascertain the appropriate treatment options for soft tissue sarcomas (STS) patients with brain metastasis (BM). PATIENTS AND METHODS: Medical records of STS patients with BM who were treated in our institutions were retrospectively reviewed, and analyzed to identify the factors associated with post-BM survival. RESULTS: Among the 509 STS patients, BM occurred in five patients (0.98%). The median survival after BM was 1.5 months. Histological subtypes of the primary lesions in the five BM patients were: two synovial sarcomas, one myxoid liposarcoma, one alveolar soft part sarcoma, and one rhabdomyosarcoma. Among the five BM patients, the post-BM survival of two patients, who underwent surgery and postoperative radiotherapy, was longer than that of the other patients (p<0.01). CONCLUSION: Combined surgery and postoperative radiotherapy effectively managed symptoms and prolonged survival in STS patients with BM.2021年02月, Anticancer research, 41(2) (2), 1027 - 1034, 英語, 国際誌研究論文（学術雑誌）
- Chondrolipoma is, based on the limited case reports available, an extremely rare histological variant of lipoma with the proliferation of mature adipocytes containing an area of true hyaline cartilage. Chondrolipoma is characterized by adult onset and is often identified in the breast, pharynx and tongue. The current study presents a case of chondrolipoma of the finger in an 11 year-old girl. Physical examination indicated a well-defined elastic soft mass, measuring 2.5x2 cm, on the dorsal aspect of the proximal phalanx of the left middle finger. Magnetic resonance imaging (MRI) revealed a well-circumscribed lesion with heterogeneous signal intensity. On T1- and T2-weighted images, the lesion indicated a predominantly marked hyperintense signal containing linear hypointense regions, and on fat-suppressed short-tau inversion recovery sequences, the lesion indicated a predominant hypointensity, with linear regions displaying hyperintensity. Marginal excision of the tumor was performed. Histologically, the major component of the tumor was mature adipose tissue containing a limited area of mature hyaline cartilage matrix, without lipoblasts or malignancy. The postoperative course of the patient was excellent, with no local recurrence three years after surgery. To the best of our knowledge, the current study outlines the first pediatric case of chondrolipoma arising in the finger.2021年01月, Molecular and clinical oncology, 14(1) (1), 2 - 2, 英語, 国際誌研究論文（学術雑誌）
- Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare, malignant tumor arising in lower extremities with no effective treatment other than wide surgical resection. Here described is a case of primary CCS in the peroneal tendon of the right foot of a 54-year-old woman enrolled to undergo BNCT. The tumor mass post-BNCT disappeared totally without damage to other normal tissue, demonstrating, for the first time, the potential efficacy of BNCT in complete local control of CCS.2020年12月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 166, 109324 - 109324, 英語, 国際誌研究論文（学術雑誌）
- Soft tissue sarcomas (STSs) are rare heterogeneous malignancies of mesenchymal origin. Pulmonary metastases develop in approximately 50% of the patients with high-grade STS, being the major cause of mortality in patients with metastatic STS. Pulmonary metastasectomy has been reported to contribute to long-term survival; however, an appropriate treatment has not been established. We aimed to identify factors associated with post-metastasis survival in STS patients with pulmonary metastasis and determine the appropriate treatment for each patient. We retrospectively reviewed the records of metastatic STS patients treated between 2000 and 2017 and analyzed the clinico-pathologic variables to identify factors associated with the survival. The median survival after pulmonary metastasis was 20.6 months, and the 1-, 3-, and 5-year survival rates were 68.6%, 36.0%, and 25.1%, respectively. The survival was significantly greater in patients who underwent pulmonary metastasectomy than in those without surgery (38.9 months vs. 10.5 months; p < 0.0001). Among those who did not undergo surgery, the survival was significantly greater in patients who received chemotherapy than in those without chemotherapy (19.1 months vs. 6.3 months, p = 0.037). Multivariate analysis identified pulmonary metastasectomy as the most important prognostic factor for post-metastasis survival (Hazard ratio 5.623; 95% Confidence Interval 2.733-11.572; p < 0.0001). In conclusion, pulmonary metastasectomy was the most important prognostic factor for post-metastasis survival in patients with metastatic STS. In addition, chemotherapy could prolong survival in patients who were not eligible for pulmonary resection. Although we should carefully weigh the risks and benefits, appropriate treatment for pulmonary metastases could contribute to long-time survival.2020年08月, Clinical & experimental metastasis, 37(4) (4), 509 - 517, 英語, 国際誌研究論文（学術雑誌）
- Ischiofemoral impingement (IFI) occurs due to the diminishing of space between the ischium and lesser trochanter. During a robotic hip study, one hip presented with indications of IFI, an opportunity to explore the pathophysiology and treatment strategies for this unusual condition. This specimen underwent kinematic tests in two states: (i) native lesser trochanter and (ii) resected lesser trochanter. The 'Resected lesser trochanter' state was found to increase the hip range of motion and decrease femoral head translation by eliminating contact between the femur and pelvis. These results suggest that lesser trochanteric resection would provide physical benefit for IFI patients.2020年08月, Journal of hip preservation surgery, 7(3) (3), 604 - 605, 英語, 国際誌研究論文（学術雑誌）
- 2020年07月, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 25(4) (4), 724 - 728, 英語, 国内誌研究論文（学術雑誌）
- Back pain is a global health problem with a high morbidity and socioeconomic burden. Intervertebral disc herniation and degeneration are its primary cause, further associated with neurological radiculopathy, myelopathy, and paralysis. The current surgical treatment is principally discectomy, resulting in the loss of spinal movement and shock absorption. Therefore, the development of disc regenerative therapies is essential. Here we show reduced disc damage by a new collagen type I-based scaffold through actinidain hydrolysis-Low Adhesive Scaffold Collagen (LASCol)-with a high 3D spheroid-forming capability, water-solubility, and biodegradability and low antigenicity. In human disc nucleus pulposus and annulus fibrosus cells surgically obtained, time-dependent spheroid formation with increased expression of phenotypic markers and matrix components was observed on LASCol but not atelocollagen (AC). In a rat tail nucleotomy model, LASCol-injected and AC-injected discs presented relatively similar radiographic and MRI damage control; however, LASCol, distinct from AC, decelerated histological disc disruption, showing collagen type I-comprising LASCol degradation, aggrecan-positive and collagen type II-positive endogenous cell migration, and M1-polarized and also M2-polarized macrophage infiltration. Reduced nucleotomy-induced disc disruption through spontaneous spheroid formation by LASCol warrants further investigations of whether it may be an effective treatment without stem cells and/or growth factors for intervertebral disc disease.2020年03月, Biomaterials, 235, 119781 - 119781, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: The prognosis of patients with metastatic or advanced sarcomas is poor and there are few options for treatment. Several studies have shown that gemcitabine and docetaxel (GD) combination chemotherapy has antitumor activity against various subtypes of sarcoma. Recently, some studies have shown a favourable outcome for GD combination chemotherapy for relapsed high-grade osteosarcoma and spindle cell sarcoma of bone. If the effectiveness of GD is proven, this will result in new treatment options for advanced bone and soft tissue sarcomas (STS). The aim of this prospective Phase 2 study is to evaluate the efficacy and toxicity of the GD combination in patients with advanced bone sarcomas and STS. METHODS: This is a Phase 2, single-arm, open-label study to investigate the efficacy and safety of combination chemotherapy with GD for advanced bone sarcomas and STS and will enrol 20 patients. The patients will receive gemcitabine 900 mg/m2 on Days 1 and 8, and docetaxel 70 mg/m2 on Day 8 in 3-week cycles until disease progression or other evidence of treatment failure. The primary aim of this study is to analyse GD's effect on progression-free survival (PFS). The secondary objectives are to analyse treatment efficacy and safety in terms of response rate, tumour control rate, overall survival, and adverse event rate. The length of follow-up will be 5 years. DISCUSSION: This study will evaluate the efficacy and safety of combination therapy with gemcitabine and docetaxel for bone sarcomas and STS. If this combination proves to be acceptable, it could be used for as second, third, or later line therapy for patients with sarcomas (especially bone sarcomas). In the future, the role of various treatments, including GD therapy, will be clarified for specific subtypes of sarcoma. TRIAL REGISTRATION: This study was registered as UMIN000031004 (University Hospital Medical Information Network-Clinical Trial Registry: UMIN-CTR) on 1 March 1 2018 and with the Japan Registry of Clinical Trials (jRCT) as jRCTs051180042 on 30 January 2019. The posted information will be updated as needed to reflect protocol amendments and study progress.2019年07月, BMC cancer, 19(1) (1), 725 - 725, 英語, 国際誌研究論文（学術雑誌）
- An infant boy underwent hip disarticulation for infantile fibrosarcoma immediately after birth. His rehabilitation began when he was 4 mos old and involved training with his left (residual) leg. He could stand with support at 12 mos. His initial prosthesis fitting was performed at the age of 13 mos. He could stand and walk with support at 15 mos of age and could walk with no additional support and go up and down stairs at 2 yrs. A single-axis prosthetic knee joint was introduced at the age of 2 yrs 3 mos. His first gait using a hip prosthesis was successful, and his prosthesis was replaced at appropriate intervals with no major problems. The authors believe that the key to achieving a successful prosthetic gait in children is good communication among the medical team, which should comprise an orthopedic doctor, rehabilitation doctor, nurse, physical therapist, prosthetist/orthotist, and the patient's parents.2018年10月, American journal of physical medicine & rehabilitation, 97(10) (10), e90-e92, 英語, 国際誌研究論文（学術雑誌）
- Hypoxia plays a significant role in cancer progression, including metastatic bone tumors. We previously reported that transcutaneous carbon dioxide (CO2) application could decrease tumor progression through the improvement of intratumor hypoxia. Therefore, we hypothesized that decreased hypoxia using transcutaneous CO2 could suppress progressive bone destruction in cancer metastasis. In the present study, we examined the effects of transcutaneous CO2 application on metastatic bone destruction using an animal model. The human breast cancer cell line MDA-MB-231 was cultured in vitro under three different oxygen conditions, and the effect of altered oxygen conditions on the expression of osteoclast-differentiation and osteolytic factors was assessed. An in vivo bone metastatic model of human breast cancer was created by intramedullary implantation of MDA-MB-231 cells into the tibia of nude mice, and treatment with 100% CO2 or a control was performed twice weekly for two weeks. Bone volume of the treated tibia was evaluated by micro-computed tomography (µCT), and following treatment, histological evaluation was performed by hematoxylin and eosin staining and immunohistochemical staining for hypoxia-inducible factor (HIF)-1α, osteoclast-differentiation and osteolytic factors, and tartrate-resistant acid phosphatase (TRAP) staining for osteoclast activity. In vitro experiments revealed that the mRNA expression of RANKL, PTHrP and IL-8 was significantly increased under hypoxic conditions and was subsequently reduced by reoxygenation. In vivo results by µCT revealed that bone destruction was suppressed by transcutaneous CO2, and that the expression of osteoclast-differentiation and osteolytic factors, as well as HIF-1α, was decreased in CO2-treated tumor tissues. In addition, multinucleated TRAP-positive osteoclasts were significantly decreased in CO2-treated tumor tissues. Hypoxic conditions promoted bone destruction in breast cancer metastasis, and reversal of hypoxia by transcutaneous CO2 application significantly inhibited metastatic bone destruction along with decreased osteoclast activity. The findings in this study strongly indicated that transcutaneous CO2 application could be a novel therapeutic strategy for treating metastatic bone destruction.2018年10月, Oncology reports, 40(4) (4), 2079 - 2087, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Chronic expanding hematoma is a rare entity resulting from trauma or surgery. This condition usually occurs in soft tissue, such as the trunk or extremities, while chronic expanding hematoma arising from bone has not been reported previously. We describe an unusual case of a huge intraosseous chronic expanding hematoma arising from the ilium, which had grown over a 40-year period following hip surgeries. CASE PRESENTATION: A 57-year-old Japanese woman presented with a 1.5-year history of right hip pain. She had a history of bilateral developmental dysplasia of the hip and had undergone bilateral arthroplasties in childhood. A physical examination revealed a large, firm, immobile mass at her right ilium. Based on radiographic findings, a type of slow-growing bone tumor was suspected, and an incisional biopsy was performed. A histopathologic examination revealed large amounts of old clotted blood within the lesion, and the capsule of the lesion was composed of dense, fibrous, connective tissue. There was no evidence of neoplasia, and chronic expanding hematoma was suspected. The lesion was resistant to conservative treatment, and so we performed an internal hemipelvectomy (including the capsule of the mass) and a reconstruction by hip transposition 2.5 years after the incisional biopsy. There was no recurrence of chronic expanding hematoma at the most recent follow-up of 1 year and 8 months postoperatively. CONCLUSIONS: A chronic expanding hematoma is characterized by its persistence and increasing size more than 1 month after the trauma or surgical event suspected of causing hemorrhage. To the best of our knowledge, this is the first report of chronic expanding hematoma arising from bone. We performed internal hemipelvectomy and hip transposition, and there has so far been no recurrence. This disease may be considered a differential diagnosis for bone tumor when the patient has a history of surgery or trauma, regardless of how many years have passed since the index event.2018年09月, Journal of medical case reports, 12(1) (1), 265 - 265, 英語, 国際誌研究論文（学術雑誌）
- Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.BACKGROUND/AIM: Second mitochondria-derived activator of caspase (Smac) is a proapoptogenic mitochondrial protein that antagonizes inhibitors of apoptosis proteins (IAPs), resulting in induction of apoptosis. In the present study we investigated the effects of a Smac mimetic in combination with doxorubicin against osteosarcoma. MATERIALS AND METHODS: In vitro effects of the combination of a Smac mimetic AT-406 and doxorubicin on cell proliferation and apoptosis in osteosarcoma cell lines were examined using cell proliferation assays, flow cytometry, and immunoblot analyses. For in vivo experiments, human osteosarcoma xenografts were treated with combination of the two substances, and tumor volume and apoptotic activity in treated tumors were assessed. RESULTS: In vitro studies revealed that combination of the two substances significantly inhibited osteosarcoma proliferation with decreased cIAP1 expression and induced apoptosis in osteosarcoma cells. Combination of the two substances significantly suppressed osteosarcoma growth in vivo. Moreover, decreased cIAP1 expression and increased apoptotic activity were observed in tumors treated by their combination of the substances. CONCLUSION: The Smac mimetic AT-406 showed an apoptotic effect and a synergistic antitumor effect with doxorubicin on osteosarcoma. The combination of AT-406 and doxorubicin may serve as a novel therapeutic strategy for osteosarcoma treatment.2017年11月, Anticancer research, 37(11) (11), 6097 - 6106, 英語, 国際誌研究論文（学術雑誌）
- Carbon dioxide (CO2) therapy can be applied to treat a variety of disorders. We previously found that transcutaneous application of CO2 with a hydrogel decreased the tumor volume of several types of tumors and induced apoptosis via the mitochondrial pathway. However, only one condition of treatment intensity has been tested. For widespread application in clinical antitumor therapy, the conditions must be optimized. In the present study, we investigated the relationship between the duration, frequency, and treatment interval of transcutaneous CO2 application and antitumor effects in murine xenograft models. Murine xenograft models of three types of human tumors (breast cancer, osteosarcoma, and malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma) were used to assess the antitumor effects of transcutaneous CO2 application of varying durations, frequencies, and treatment intervals. In all human tumor xenografts, apoptosis was significantly induced by CO2 treatment for ≥10 min, and a significant decrease in tumor volume was observed with CO2 treatments of >5 min. The effect on tumor volume was not dependent on the frequency of CO2 application, i.e., twice or five times per week. However, treatment using 3- and 4-day intervals was more effective at decreasing tumor volume than treatment using 2- and 5-day intervals. The optimal conditions of transcutaneous CO2 application to obtain the best antitumor effect in various tumors were as follows: greater than 10 min per application, twice per week, with 3- and 4-day intervals, and application to the site of the tumor. The results suggest that this novel transcutaneous CO2 application might be useful to treat primary tumors, while mitigating some side effects, and therefore could be safe for clinical trials.2017年06月, Oncology reports, 37(6) (6), 3688 - 3694, 英語, 国際誌研究論文（学術雑誌）
- The AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) modulates cellular energy metabolism, and promotes mitochondrial proliferation and apoptosis. Previous studies have shown that AICAR has anticancer effects in various cancers, however the roles of AMPK and/or the effects of AICAR on osteosarcoma have not been reported. In the present study, we evaluated the effects of AICAR on tumor growth and mitochondrial apoptosis in human osteosarcoma both in vitro and in vivo. For in vitro experiments, two human osteosarcoma cell lines, MG63 and KHOS, were treated with AICAR, and the effects of AICAR on cell growth and mitochondrial apoptosis were assessed by WST assays, TUNEL staining, and immunoblot analyses. In vivo, human osteosarcoma-bearing mice were treated with AICAR, and the mitochondrial proliferation and apoptotic activity in treated tumors were assessed. In vitro experiments revealed that AICAR activated AMPK, inhibited cell growth, and induced mitochondrial apoptosis in both osteosarcoma cell lines. In vivo, AICAR significantly reduced osteosarcoma growth without apparent body weight loss and AICAR increased both mitochondrial proliferation and apoptotic activity in treated tumor tissues. AICAR showed anticancer effects in osteosarcoma cells through an AMPK-dependent peroxisome proliferator‑activated receptor-γ coactivator-1α (PGC-1α)/mitochondrial transcription factor A (TFAM)/mitochondrial pathway. The findings in this study strongly suggest that AICAR could be considered as a potent therapeutic agent for the treatment of human osteosarcoma.2017年01月, International journal of oncology, 50(1) (1), 23 - 30, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. METHODS: Forty-eight patients (average age: 52 years [range 14-88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2-273). RESULTS: The 5-year overall survival rates and disease-free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease-free survival. CONCLUSIONS: This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495-500. © 2016 Wiley Periodicals, Inc.2016年09月, Journal of surgical oncology, 114(4) (4), 495 - 500, 英語, 国際誌研究論文（学術雑誌）
- Malignant peripheral nerve sheath tumors (MPNST) are relatively rare neoplasms with poor prognosis. At present there is no effective treatment for MPNST other than surgical resection. Nonetheless, the anti-tumor effect of boron neutron capture therapy (BNCT) was recently demonstrated in two patients with MPNST. Subsequently, tumor-bearing nude mice subcutaneously transplanted with a human MPNST cell line were injected with p-borono-L-phenylalanine (L-BPA) and subjected to BNCT. Pathological studies then revealed that the MPNST cells were selectively destroyed by BNCT.2015年12月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 106, 220 - 5, 英語, 国際誌研究論文（学術雑誌）
- Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In the present study, we established a lung metastasis animal model of CCS and investigated the therapeutic effect of boron neutron capture therapy (BNCT) using p-borono-L-phenylalanine (L-BPA). Biodistribution data revealed tumor-selective accumulation of (10)B. Unlike conventional gamma-ray irradiation, BNCT significantly suppressed tumor growth without damaging normal tissues, suggesting that it may be a potential new therapeutic option to treat CCS lung metastases.2015年12月, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 106, 195 - 201, 英語, 国際誌研究論文（学術雑誌）
- Decoy receptor 3 (DcR3) is a soluble secreted protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. DcR3 inhibits the Fas ligand (FasL)/Fas apoptotic pathway by binding to FasL, competitively with Fas receptor. Previous studies have reported that overexpression of DcR3 has been detected in various human malignancies and that DcR3 functions as a 'decoy' for FasL to inhibit FasL-induced apoptosis. In addition, recent studies have revealed that DcR3 has 'non-decoy' functions to promote tumor cell migration and invasion, suggesting that DcR3 may play important roles in tumor progression by decoy and non-decoy functions. We have previously reported that overexpression of DcR3 was observed in human malignant fibrous histiocytoma (MFH), however, the roles of DcR3 in MFH have not been studied. In the present study, to elucidate the roles of DcR3 in tumor progression of MFH, we examined the effects of DcR3 inhibition on cell apoptosis, migration and invasion in human MFH cells. siRNA knockdown of DcR3 enhanced the FasL-induced apoptotic activity and significantly decreased cell migration and invasion with a decrease in the activation of phosphatidylinositol 3 kinase (PI3K)/Akt and matrix metalloproteinase (MMP)-2. The findings in this study strongly suggest that DcR3 plays important roles in tumor progression of human MFH by decoy as well as non-decoy functions and that DcR3 may serve as a potent therapeutic target for human MFH.2013年09月, International journal of oncology, 43(3) (3), 703 - 12, 英語, 国際誌研究論文（学術雑誌）
- Osteosarcoma is the most common primary solid malignant bone tumor. Despite substantial improvements in surgery and chemotherapy, metastasis remains a major cause of fatal outcomes, and the molecular mechanisms of metastasis are still poorly understood. Hypoxia, which is common in malignant tumors including osteosarcoma, increases expressions of hypoxia inducible factor (HIF)-1α, matrix metalloproteinase (MMP)-2 and MMP-9, and can induce invasiveness. As we previously showed a novel transcutaneous CO2 application to decrease HIF-1α expression and induce apoptosis in malignant fibrous histiocytoma, we hypothesize that transcutaneous CO2 application could suppress metastatic potential of osteosarcoma by improving hypoxic conditions. Here, we examined the effects of transcutaneous CO2 application on apoptosis, and development of pulmonary metastasis using a highly metastatic osteosarcoma cell line, LM8. Transcutaneous CO2 application significantly decreased tumor growth and pulmonary metastasis in LM8 cells. Apoptotic activity increased, and intratumoral hypoxia was improved with decreased expressions of HIF-1α, MMP-2 and MMP-9, significantly, in the CO2-treated tumors. In conclusion, we found that transcutaneous CO2 application can induce tumor cell apoptosis and might suppress pulmonary metastasis by improvement of hypoxic conditions with decreased expressions of HIF-1α and MMPs in highly metastatic osteosarcoma cell. These findings strongly indicate that this novel transcutaneous CO2 therapy could be a therapeutic breakthrough for osteosarcoma patients.2013年08月, Experimental cell research, 319(13) (13), 1988 - 1997, 英語, 国際誌研究論文（学術雑誌）
- Osteosarcoma (OS) is a primary malignancy of the bone, with a tendency to metastasize early. Despite intensive chemotherapy and surgical resection, more than 30% of patients develop distant metastases, and the prognosis of patients with metastases is essentially poor. Members of the protein kinase D (PKD) family are serine/threonine kinases, and have been studied in various cancers. Among the three different isoforms of this family, PKD1 is one of the best understood for its role in human malignancies; however, its role in musculoskeletal tumors has not been studied. In the present study, we investigated the role of PKD1 in human OS. We first analyzed PKD1 mRNA expression in human musculoskeletal tumor tissue samples by quantitative real-time PCR. PKD1 expression in OS samples was significantly lower than that in benign schwannoma samples, and this was correlated with metastatic potential. In in vitro studies, overexpression of PKD1 by plasmid transfection decreased OS cell invasion, migration and proliferation, and significantly decreased matrix metalloproteinase (MMP)2 mRNA expression. Conversely, siRNA knockdown of PKD1 increased invasion, migration and proliferation of OS cells, and MMP2 expression was markedly increased. Furthermore, overexpression of PKD1 significantly reduced in vivo tumor growth of OS cells. These results demonstrated that low expression of PKD1 may contribute to increased cell invasion, migration and proliferation ability of human OS. Taken together, our findings strongly suggest that PKD1 may negatively regulate the malignant potential of human OS, and may be a therapeutic target for human OS in the clinical setting.2012年06月, International journal of oncology, 40(6) (6), 1839 - 48, 英語, 国際誌研究論文（学術雑誌）
- Mitochondria play an essential role in cellular energy metabolism and apoptosis. Previous studies have demonstrated that decreased mitochondrial biogenesis is associated with cancer progression. In mitochondrial biogenesis, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) regulates the activities of multiple nuclear receptors and transcription factors involved in mitochondrial proliferation. Previously, we showed that overexpression of PGC-1α leads to mitochondrial proliferation and induces apoptosis in human malignant fibrous histiocytoma (MFH) cells in vitro. We also demonstrated that transcutaneous application of carbon dioxide (CO(2)) to rat skeletal muscle induces PGC-1α expression and causes an increase in mitochondrial proliferation. In this study, we utilized a murine model of human MFH to determine the effect of transcutaneous CO(2) exposure on PGC-1α expression, mitochondrial proliferation and cellular apoptosis. PGC-1α expression was evaluated by quantitative real-time PCR, while mitochondrial proliferation was assessed by immunofluorescence staining and the relative copy number of mitochondrial DNA (mtDNA) was assessed by real-time PCR. Immunofluorescence staining and DNA fragmentation assays were used to examine mitochondrial apoptosis. We also evaluated the expression of mitochondrial apoptosis related proteins, such as caspases, cytochorome c and Bax, by immunoblot analysis. We show that transcutaneous application of CO(2) induces PGC-1α expression, and increases mitochondrial proliferation and apoptosis of tumor cells, significantly reducing tumor volume. Proteins involved in the mitochondrial apoptotic cascade, including caspase 3 and caspase 9, were elevated in CO(2) treated tumors compared to control. We also observed an enrichment of cytochrome c in the cytoplasmic fraction and Bax protein in the mitochondrial fraction of CO(2) treated tumors, highlighting the involvement of mitochondria in apoptosis. These data indicate that transcutaneous application of CO(2) may represent a novel therapeutic tool in the treatment of human MFH.2012年, PloS one, 7(11) (11), e49189, 英語, 国際誌研究論文（学術雑誌）
- Protein kinase Cδ (PKCδ), an isoform of PKC, has been shown to act as a critical mediator of tumor progression and apoptosis; however, its role in musculoskeletal tumors is still unknown. In the current study, we examined the expression of PKCδ in human musculoskeletal tumor tissue samples, and investigated the effects of siRNA downregulation of PKCδ on human malignant fibrous histiocytoma (MFH) cell proliferation, migration, and apoptosis, to elucidate its functional roles in musculoskeletal tumorigenesis. Of note, real-time PCR analysis revealed that mRNA expression of PKCδ in high-grade musculoskeletal MFH tumors was significantly lower than that in benign schwannomas. siRNA downregulation of PKCδ significantly increased human MFH cell proliferation and migration, and markedly suppressed apoptosis. These findings suggest that PKCδ has a negative effect on tumorigenesis and/or acts as a pro-apoptotic kinase in human MFH cells. The data presented here could be applied in the development of new therapeutic avenues, with the elevation of PKCδ expression being one potential strategy to prevent MFH progression. Thus, PKCδ may be a potent therapeutic target for human MFH.2011年11月, Oncology reports, 26(5) (5), 1221 - 6, 英語, 国際誌研究論文（学術雑誌）
- One-staged tibial corrective osteotomy and total knee arthroplasty is a challenging but effective treatment for arthritic knees with extra-articular deformity. Although osteocutaneous thermal necrosis is accepted as a complication of intramedullary reamed nailing following long bone fractures, only 15 cases have been reported in the English literature at present. This report illustrates a rare case of thermal necrosis in a patient undergoing tibial corrective osteotomy coincident with long-stemmed total knee arthroplasty. Excessive reaming with a machine reamer is hypothesized as the cause of this serious complication. In this report, we highlight this rare but serious complication after long-stemmed total knee arthroplasty.2011年01月, Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 19(1) (1), 112 - 4, 英語, 国際誌研究論文（学術雑誌）
- The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model.BACKGROUND: Bevacizumab is a specific inhibitor of angiogenesis and a neutralising antibody against vascular endothelial growth factor (VEGF). The effect of bevacizumab was evaluated on malignant fibrous histiocytoma (MFH) in vivo using an animal model. MATERIALS AND METHODS: MFH cell line, NaraH, was implanted to athymic nude mice which were randomly divided into a treatment and a control group. The change in body weight and tumour volume were evaluated and immunohistochemical analysis was performed of microvessel density (MVD) and VEGF expression in the tumour tissue. RESULTS: Bevacizumab significantly induced inhibition of tumour growth, reducing tumour volume to 48% at the end of experiment. Intratumoural MVD was significantly decreased in the bevacizumab treatment group compared to the control group. A positive correlation was found between tumour volume and MVD. CONCLUSION: Bevacizumab suppressed MFH tumour growth by inhibiting tumoural angiogenesis. The current study suggests that bevacizumab may be a novel therapeutic agent for MFH.2010年09月, Anticancer research, 30(9) (9), 3391 - 5, 英語, 国際誌研究論文（学術雑誌）
- Influence of intra-operative joint gap on post-operative flexion angle in osteoarthritis patients undergoing posterior-stabilized total knee arthroplasty.Recently, we developed a new tensor for total knee arthroplasty (TKA) procedures enabling soft tissue balance assessment throughout the range of motion while reproducing post-operative joint alignment with the patello-femoral (PF) joint reduced and the tibiofemoral joint aligned. Using the tensor with a computer-assisted navigation system, we investigated the relationship between various intra-operative joint gap values and their post-operative flexion angles. An increased value during the extension to flexion gap and a decreased value during the flexion to deep flexion gap with PF joint reduced, not everted, showed an inverse correlation with post-operative knee flexion angle, not pre-operative flexion angle. In conclusion, understanding the characteristics of joint gap kinematics in posterior-stabilized TKA under physiological and reproducible joint conditions may enable the prediction of the post-operative flexion angle and help to determine the appropriate intra-operative joint gap.2007年08月, Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 15(8) (8), 1013 - 8, 英語, 国際誌研究論文（学術雑誌）
- Usefulness of MRI for diagnosis of painful snapping elbow.Painful snapping of the elbows is rare. We report on a 12-year-old boy with a painful snap in both elbows. High-resolution magnetic resonance imaging of the elbow using microscopy coils detected a synovial fold interposed in each humeroradial joint and was very helpful in establishing the cause of symptoms. Resection of the synovial folds was performed with subsequent relief of symptoms.2006年10月, Skeletal radiology, 35(10) (10), 797 - 800, 英語, 国際誌研究論文（学術雑誌）
- 2025年, 中部日本整形外科災害外科学会雑誌, 68上肢骨転移に対する手術成績
- 2025年, 日本整形外科学会雑誌(CD-ROM), 99(3) (3)Ewing肉腫の病態解明と新規治療標的の探索-次世代シーケンサーを用いた網羅的遺伝子解析によるSlow-Cycling Cellsの検討-
- 2025年, 日本整形外科学会雑誌(CD-ROM), 99(3) (3)Compress型インプラントを用いた腫瘍用人工関節置換術例の検討
- 2024年, 中部日本整形外科災害外科学会雑誌, 67(2) (2)30年の経過を経てchronic expanding hematomaを合併し増大した大腿部gossypiboma(ガーゼオーマ)の1例
- 2024年, 日本整形外科学会雑誌, 98(2) (2)骨転移診断ガイドラインから見た骨転移に対する薬物療法
- 2024年, 中部日本整形外科災害外科学会雑誌, 67骨肉腫細胞におけるSPRR1Aの機能の探索-新規開発骨肉腫がん幹細胞様細胞を用いた検討
- 2024年, 中部日本整形外科災害外科学会雑誌, 67膝関節内に巨大腫瘤を形成し腱滑膜巨細胞腫との鑑別を要した滑膜軟骨腫症の一例
- 2024年, 中部日本整形外科災害外科学会雑誌, 67肘部管症候群を合併した右肘滑膜軟骨腫症の一例
- 2024年, 中部日本整形外科災害外科学会雑誌, 67Ewing肉腫におけるslow-cycling-cellsの特性の探索-次世代シーケンス解析を用いた検討
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)術前に陽子線を照射した粘液型脂肪肉腫の2例
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)Compress型インプラントによる腫瘍用人工関節置換術例の検討
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)転移性骨腫瘍に対するデノスマブ長期投与中止後の調査
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)骨肉腫細胞におけるSPRR1Aの機能の探索-新規開発骨肉腫がん幹細胞様細胞を用いた検討-
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)Ewing肉腫におけるslow-cycling-cellsの特性の探索
- 2024年, 中部日本整形外科災害外科学会雑誌, 67四肢骨転移に対する治療の現状と課題
- 2024年, 中部日本整形外科災害外科学会雑誌, 67自身のキャリア形成の現状と課題-1度手術を手放した私が再び手術を学ぶチャンスをつかむまで-
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(8) (8)網羅的遺伝子解析を用いたEwing肉腫におけるslow-cycling-cellsの特性の探索
- 2024年, 日本整形外科学会雑誌(CD-ROM), 98(8) (8)骨肉腫細胞におけるSPRR1Aの機能の探索-新規開発骨肉腫がん幹細胞様細胞を用いた検討-
- 2023年, 日本整形外科学会雑誌, 97(3) (3)本邦における骨盤発生悪性骨・軟部腫瘍の臨床成績と予後因子の検討
- 2023年, 日本整形外科学会雑誌, 97(6) (6)化学療法と炭素イオン線治療により5年生存し,歩行機能を温存しえた71歳の寛骨臼骨肉腫の1例
- 2023年, 日本整形外科学会雑誌, 97(6) (6)骨肉腫細胞におけるSPRR1Aの機能の探索
- 2023年, 日本整形外科学会雑誌, 97(6) (6)本邦における骨盤発生悪性骨・軟部腫瘍に対する手術と粒子線の治療成績の比較
- 2023年, 日本整形外科学会雑誌, 97(6) (6)小児中足骨発生の類上皮血管内皮腫の1例
- 2023年, 日本整形外科学会雑誌, 97(8) (8)骨肉腫細胞におけるSPRR1Aの機能の探索
- 2023年, 中部日本整形外科災害外科学会雑誌, 6630年の経過を経てChronic expanding hematomaを合併し増大した大腿部Gossypiboma(ガーゼオーマ)の1例
- 2023年, Japanese Journal of Rehabilitation Medicine, 60(Autumn) (Autumn)骨転移患者に対するリハビリテーション治療効果:傾向スコアマッチングを用いた検討
- 2023年, 中部日本整形外科災害外科学会雑誌, 66足趾に生じた粘液型脂肪肉腫の一例
- 2022年, 中部日本整形外科災害外科学会雑誌, 65手足に生じた軟部肉腫の予後に関する検討
- 2022年, 日本整形外科学会雑誌, 96(6) (6)腹腔外デスモイド型線維腫症に対するWait&Seeの治療成績
- 2022年, 日本整形外科学会雑誌, 96(6) (6)骨盤発生悪性骨・軟部腫瘍の治療成績と予後因子の検討
- 2022年, 日本整形外科学会雑誌, 96(6) (6)悪性末梢神経鞘腫瘍の治療成績
- 2022年, 日本整形外科学会雑誌, 96(6) (6)骨肉腫肺転移症例の検討
- 2022年, 日本整形外科学会雑誌, 96(6) (6)手足に生じた軟部肉腫の治療成績と予後因子に関する検討
- 2022年, 日本整形外科学会雑誌, 96(6) (6)Ewing肉腫におけるslow-cycling cellの同定
- 2022年, 日本整形外科学会雑誌, 96(8) (8)Ewing肉腫におけるslow-cycling cellsの同定
- 2022年, 日本整形外科学会雑誌, 96(8) (8)骨肉腫細胞におけるsprr1aの機能の探索
- 2022年, 中部日本整形外科災害外科学会雑誌, 65(5) (5)内軟骨腫との鑑別を要した小児中足骨発生の類上皮血管内皮腫の1例
- 2022年, Japanese Journal of Rehabilitation Medicine, 59(Supplement) (Supplement)両大腿骨切迫骨折に対し,両側髄内定固定術を施行された一症例
- 2022年, 中部日本整形外科災害外科学会雑誌, 65軟骨肉腫との鑑別を要した骨盤軟骨粘液線維腫の一例
- 2021年, 日本整形外科学会雑誌, 95(6) (6)乳癌骨転移における骨破壊に寄与するmiRNAの探索
- 2020年, 日本整形外科学会雑誌, 94(6) (6)がん骨転移における骨破壊に寄与するmiRNAの探索
- 2020年, 日本整形外科学会雑誌, 94(8) (8)乳癌骨転移における骨破壊に寄与するmiRNAの探索
- (一社)中部日本整形外科災害外科学会, 2019年05月, 中部日本整形外科災害外科学会雑誌, 62(3) (3), 595 - 595, 日本語膝関節軟骨穿破を伴ったBrodie膿瘍を長期経過観察した1例
- (一社)中部日本整形外科災害外科学会, 2019年05月, 中部日本整形外科災害外科学会雑誌, 62(3) (3), 595 - 595, 日本語膝関節軟骨穿破を伴ったBrodie膿瘍を長期経過観察した1例
- 2019年, 日本再生医療学会総会(Web), 18thリプログラミング因子を用いた人工骨肉腫幹細胞株の樹立
- 2019年, 日本整形外科学会雑誌, 93(6) (6)リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立
- 2019年, 日本整形外科学会雑誌, 93(6) (6)右足部軟部腫瘍の1例
- 2019年, 日本整形外科学会雑誌, 93(6) (6)Wait & see policyで初回治療を行った腹腔外デスモイド型線維腫症の検討
- 2019年, Japanese Journal of Rehabilitation Medicine, 56(Supplement) (Supplement)四肢転移性骨腫瘍に対する外科的治療成績について
- 2019年, 日本整形外科学会雑誌, 93(6) (6)明細胞肉腫に対するLAT1阻害剤の抗腫瘍効果の検討
- 2019年, 日本整形外科学会雑誌, 93(6) (6)骨・軟部肉腫における脳転移症例の検討
- 2019年, Journal of Spine Research, 10(5) (5)脊椎転移に対する手術療法の効果と限界
- 2019年, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 35th軟部肉腫の診断と治療-整形外科骨軟部腫瘍専門医の経験と提言-
- 2019年, 日本整形外科学会雑誌, 93(6) (6)粘液型脂肪肉腫の治療成績
- 2019年, 日本整形外科学会雑誌, 93(3) (3)四肢の腎癌骨転移に対して手術を施行した症例の検討
- 2019年, 中部日本整形外科災害外科学会雑誌, 62四肢の腎癌骨転移に対して手術を施行した症例の検討
- 2019年, 日本整形外科学会雑誌, 93(8) (8)リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立とその特性の探索
- 2019年, 日本整形外科学会雑誌, 93(8) (8)がん骨転移における骨破壊に寄与するmiRNAの同定
- (公社)日本リハビリテーション医学会, 2018年10月, The Japanese Journal of Rehabilitation Medicine, 55(秋季特別号) (秋季特別号), S274 - S274, 日本語70歳以上の脊椎転移患者の手術成績 PS、ADL、QOLの推移から
- (公社)日本リハビリテーション医学会, 2018年10月, The Japanese Journal of Rehabilitation Medicine, 55(秋季特別号) (秋季特別号), S357 - S357, 日本語炭酸ガス経皮吸収による低酸素環境の改善が乳がん骨転移モデルの骨破壊を抑制する
- (公社)日本リハビリテーション医学会, 2018年10月, The Japanese Journal of Rehabilitation Medicine, 55(秋季特別号) (秋季特別号), S367 - S367, 日本語脊椎転移の症候化リスク因子の前向き検討
- 2018年, 日本整形外科学会雑誌, 92(3) (3)Low-grade fibromyxoid sarcoma(Evans tumor)の臨床病理学的検討-診断におけるFUS break-apart FISHの有用性-
- 2018年, 臨床整形外科, 53(7) (7)全身画像検索が診断に有用であった慢性再発性多発性骨髄炎の2例
- 2018年, 日本整形外科学会雑誌, 92(3) (3)悪性軟部腫瘍肺転移症例における予後因子
- 2018年, 骨折, 40(Supplement) (Supplement)大腿骨近位部病的骨折:人工関節の適応と限界
- 2018年, 日本整形外科学会雑誌, 92(6) (6)脊椎転移に対する手術療法の効果
- 2018年, 日本整形外科学会雑誌, 92(6) (6)粘液線維肉腫の治療成績
- 2018年, 日本整形外科学会雑誌, 92(6) (6)経皮炭酸ガス吸収による低酸素環境の改善は乳癌骨転移モデルの骨破壊を抑制する
- 2018年, 日本整形外科学会雑誌, 92(8) (8)iPS作製技術を用いた人工骨肉腫幹細胞株の樹立
- 2018年, Japanese Journal of Rehabilitation Medicine, 55(Supplement) (Supplement)経皮炭酸ガス吸収による低酸素環境の改善は乳癌骨転移モデルの骨破壊を抑制できる
- 2018年, Journal of Spine Research, 9(3) (3)細胞低接着性コラーゲン(Low Adhesive Scaffold Collagen:LASCol)による脊椎椎間板再生の可能性
- 2018年, 日本整形外科学会雑誌, 92(8) (8)新規低接着性scaffold collagen(LASCol)はラット骨欠損モデルにおいて骨癒合を促進する
- 2018年, 多血小板血漿(PRP)療法研究会プログラム・抄録集, 10th細胞低接着性コラーゲン(LASCol)を用いた脊椎椎間板再生の可能性
- 2018年, 日本整形外科学会雑誌, 92(8) (8)細胞低接着性コラーゲン(low adhesive scaffold collagen:LASCol)を用いた脊椎椎間板再生の試み
- 2018年, 日本整形外科学会雑誌, 92(6) (6)Low-grade fibromyxoid sarcoma(Evans tumor)の臨床病理学的検討-診断におけるFISHの有用性
- 2018年, Japanese Journal of Rehabilitation Medicine, 55(Supplement) (Supplement)新規低接着性コラーゲン(LASCol)はラット大腿骨骨欠損モデルにおいて骨癒合を促進する
- 2018年, Japanese Journal of Rehabilitation Medicine, 55(Supplement) (Supplement)細胞低接着性コラーゲン(Low Adhesive Scaffold Collagen:LASCol)による脊椎椎間板再生
- 2018年, 日本整形外科学会雑誌, 92(6) (6)四肢の腎癌骨転移に対して手術を施行した症例の検討
- 2018年, 日本整形外科学会雑誌, 92(6) (6)初発転移が膵であった腓骨原発骨肉腫の1例
- 2018年, 中部日本整形外科災害外科学会雑誌, 61小児の手指に発生したchondrolipomaの1例
- 2017年, 日本整形外科学会雑誌, 91(2) (2)Low-grade fibromyxoid sarcoma(Evans tumor)の診断における分子遺伝学的解析の有用性
- 2017年, 中部日本整形外科災害外科学会雑誌, 60大腿骨に発生したFGF23産生腫瘍による腫瘍性骨軟化症の1例
- 2017年, 日本整形外科学会雑誌, 91(3) (3)骨転移診療の現状と各診療科の意識調査-整形外科医・腫瘍内科医・放射線治療医に対するアンケート-
- 2017年, 日本整形外科学会雑誌, 91(6) (6)四肢転移性骨腫瘍患者に対する理学療法の現状
- 2017年, 日本整形外科学会雑誌, 91(6) (6)経皮炭酸ガス吸収による低酸素環境の改善はがん骨転移部の骨破壊を抑制する
- 2017年, 日本整形外科学会雑誌, 91(6) (6)悪性軟部腫瘍肺転移に対する切除術の治療成績
- 2017年, 日本整形外科学会雑誌, 91(6) (6)症候性脊椎転移の発生リスクに関する前向き研究
- 2017年, 日本整形外科学会雑誌, 91(2) (2)Chronic expanding hematomaのMRI画像の特徴と軟部肉腫との鑑別についての検討
- 2017年, 整形外科最小侵襲手術ジャーナル, (84) (84)転移性脊椎腫瘍に対する最小侵襲脊椎安定術(MISt)転移性脊椎腫瘍に対する出張型骨転移Cancer Boardの取り組み
- 2017年, 中部日本整形外科災害外科学会雑誌, 60全身画像検索が診断に有用であった慢性再発性多発性骨髄炎(CRMO)の2例
- 2017年, 日本整形外科学会雑誌, 91(8) (8)炭酸ガス経皮吸収による低酸素環境の改善は乳癌骨転移による骨破壊を抑制する
- 2017年, 日本整形外科学会雑誌, 91(6) (6)転移性骨腫瘍に対する腫瘍用人工関節の術後成績
- 2017年, 日本整形外科学会雑誌, 91(2) (2)骨・軟部悪性腫瘍における肺転移切除例の治療成績
- 2017年, 中部日本整形外科災害外科学会雑誌, 60転移性骨腫瘍に対する腫瘍用人工関節の術後成績
- 2017年, 日本整形外科学会雑誌, 91(6) (6)悪性骨・軟部腫瘍に対する重粒子線治療の長期成績
- 2017年, 日本整形外科学会雑誌, 91(6) (6)Low-grade fibromyxoid sarcoma(Evans tumor)の診断におけるFISHの有用性
- (一社)日本小児血液・がん学会, 2016年11月, 日本小児血液・がん学会雑誌, 53(4) (4), 298 - 298, 日本語G-CSF投与と自家末梢血幹細胞移植を併用しbi-weekly VDC-IE療法を完遂し得た切除不能ユーイング肉腫例
- 2016年, 中部日本整形外科災害外科学会雑誌, 59乳幼児に股関節義足を作成し歩行を獲得した一例
- 2016年, 日本整形外科学会雑誌, 90(6) (6)進行骨・軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の治療成績
- 2016年, 日本整形外科学会雑誌, 90(6) (6)AICARの骨肉腫細胞に対するアポトーシス誘導効果
- 2016年, 日本整形外科学会雑誌, 90(3) (3)当院における四肢転移性骨腫瘍に対する外科的治療成績
- 2016年, 日本整形外科学会雑誌, 90(8) (8)骨転移部位の低酸素環境の改善は乳癌骨転移による骨破壊を抑制する
- 2016年, 日本整形外科学会雑誌, 90(6) (6)転移性脊椎腫瘍患者に対する理学療法の現状
- 2016年, 日本整形外科学会雑誌, 90(6) (6)悪性末梢神経鞘腫瘍(MPNST:malignant peripheral nerve sheath tumor)の治療成績
- 2016年, 中部日本整形外科災害外科学会雑誌, 59腸骨に発生したchronic expanding hematomaの1例
- 2016年, 中部日本整形外科災害外科学会雑誌, 59軟骨肉腫に対する粒子線治療の検討
- 2016年, 中部日本整形外科災害外科学会雑誌, 59(5) (5)乳幼児に股義足を作成し歩行を獲得した1例
- 2016年, 日本臨床腫瘍学会学術集会(CD-ROM), 14th進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の治療成績
- 2016年, 臨床整形外科, 51(7) (7)二酸化炭素の経皮吸収による悪性腫瘍の抗腫瘍効果
- 2016年, 日本整形外科学会雑誌, 90(6) (6)Low-grade fibromyxoid sarcoma(Evans tumor)の臨床病理学的検討
- 2016年, 日本整形外科学会雑誌, 90(8) (8)骨肉腫細胞に対するSmac模倣薬とドキソルビシンの併用効果の検討
- 2016年, 日本整形外科学会雑誌, 90(8) (8)AICARの骨肉腫細胞に対するアポトーシス誘導効果
- 2016年, 日本整形外科学会雑誌, 90(6) (6)低酸素環境改善は乳癌細胞において破骨細胞誘導因子と溶骨性因子の発現を低下させる
- 2016年, 日本小児血液・がん学会雑誌(Web), 53(4) (4)G-CSF投与と自家末梢血幹細胞移植を併用しbi-weekly VDC-IE療法を完遂し得た切除不能ユーイング肉腫例
- 2016年, 中部日本整形外科災害外科学会雑誌, 59当院における四肢転移性骨腫瘍に対する外科的治療の現状と治療成績
- 2015年, 日本整形外科学会雑誌, 89(3) (3)骨原発性平滑筋肉腫の治療成績-骨軟部肉腫治療研究会(JMOG)多施設共同研究-
- 2015年, 日本整形外科学会雑誌, 89(4) (4)四肢発生の転移性骨腫瘍に対する治療法の選択
- 2015年, 日本整形外科学会雑誌, 89(3) (3)慢性血腫と鑑別を要した軟部肉腫のMR像
- 2015年, 日本整形外科学会雑誌, 89(6) (6)Mirels’ratingを用いた大腿骨転移の病的骨折リスク評価と手術適応
- 2015年, 日本整形外科学会雑誌, 89(6) (6)骨巨細胞腫の治療成績
- 2015年, 中部日本整形外科災害外科学会雑誌, 58(4) (4)RAOの手技を用いて関節包外切除を行った大腿骨近位部骨肉腫の2例
- 2015年, 日本整形外科学会雑誌, 89(6) (6)リンパ節転移に対するホウ素中性子捕捉療法(BNCT)の可能性-乳癌の腋窩リンパ節転移症例からの検討-
- 2015年, 中部日本整形外科災害外科学会雑誌, 58(5) (5)初発転移が膵であった腓骨原発骨肉腫の1例
- 2015年, 中部日本整形外科災害外科学会雑誌, 58後骨間神経麻痺を呈した前腕脂肪腫の一例
- 2015年, 中部日本整形外科災害外科学会雑誌, 58RAOの手技を用いて広範切除を行った大腿骨近位部骨肉腫の2例
- 2015年, 日本整形外科学会雑誌, 89(6) (6)初回治療後44年を経て悪性転化を来した腱鞘巨細胞腫の1例
- 2015年, 日本形成外科学会会誌, 35(10) (10)Proximal type epithelioid sarcoma(近位型類上皮肉腫)の1例
- 2014年, 日本整形外科学会雑誌, 88(2) (2)ホウ素中性子捕捉療法(BNCT)を用いた転移性肺腫瘍に対する新たな治療方法の開発-明細胞肉腫の単発性肺転移モデルを用いた検討-
- 2014年, 日本整形外科学会雑誌, 88(2) (2)四肢発生の転移性骨腫瘍に対する治療法の選択
- 2014年, 日本整形外科学会雑誌, 88(3) (3)重粒子線治療後に局所再発を来した悪性骨・軟部腫瘍の検討
- 2014年, 日本整形外科学会雑誌, 88(6) (6)悪性末梢神経鞘腫瘍(MPNST)に対するホウ素中性子捕捉療法(BNCT)を用いた新たな治療方法
- 2014年, 中部日本整形外科災害外科学会雑誌, 57(1) (1)骨盤悪性骨腫瘍に対する重粒子線治療後の大腿骨頭壊死が患肢機能に及ぼす影響
- 2014年, 日本整形外科学会雑誌, 88(6) (6)病的骨折を来した四肢発生転移性骨腫瘍の治療成績
- 2014年, 日本整形外科学会雑誌, 88(6) (6)初診時に血腫と診断された軟部肉腫の検討
- 2013年, 日本整形外科学会雑誌, 87(6) (6)粘液線維肉腫へのホウ素中性子捕捉療法(BNCT)適用についての検討
- 2013年, 日本整形外科学会雑誌, 87(6) (6)遠隔転移を来した軟部肉腫の予後因子の解析
- 2013年, 日本整形外科学会雑誌, 87(6) (6)脱分化過程を画像にて追跡しえた胸壁発生の脱分化型脂肪肉腫の1例
- 2013年, 中部日本整形外科災害外科学会雑誌, 56骨盤悪性骨腫瘍に対する重粒子線治療後の大腿骨頭壊死が患肢機能に及ぼす影響
- 2013年, 中部日本整形外科災害外科学会雑誌, 56(2) (2)大腿骨遠位骨腫瘍に対する腫瘍用人工膝関節置換術後の膝蓋骨低位症の検討
- 2013年, 日本臨床腫瘍学会学術集会(CD-ROM), 11th当院でパゾパニブを投与した手術不能/再発軟部肉腫7名の症例報告
- 2013年, 日本整形外科学会雑誌, 87(6) (6)高純度β-リン酸三カルシウム(β-TCP)を骨補填材料として使用した良性骨腫瘍の治療成績
- 2012年, 中部日本整形外科災害外科学会雑誌, 55大腿骨遠位骨腫瘍に対する腫瘍用人工膝関節置換術後の膝蓋骨低位症の検討
- 2012年, 日本整形外科学会雑誌, 86(6) (6)DcR3はMMP発現を介してヒトMFH細胞の遊走能および浸潤能を制御する
- 2012年, 日本整形外科学会雑誌, 86(6) (6)炭酸ガス経皮投与療法を用いたヒトMFHに対する新しい治療法
- 2012年, 日本整形外科学会雑誌, 86(8) (8)ヒトMFH細胞におけるDcR3の増殖能・遊走能・浸潤能に対する影響の検討
- 2012年, 日本整形外科学会雑誌, 86(8) (8)炭酸ガス経皮投与はMMP群の発現を抑制することで骨肉腫細胞の肺転移能を低下させる
- 2012年, 日本整形外科学会雑誌, 86(6) (6)低酸素環境の改善はヒトMFH細胞においてミトコンドリア量を増加させる
- 2012年, 日本整形外科学会雑誌, 86(3) (3)DcR3発現抑制はMFH細胞において細胞遊走能および浸潤能を抑制し,FasLによるアポトーシスを亢進させる
- 2011年, 日本整形外科学会雑誌, 85(8) (8)悪性線維性組織球腫細胞株に対する血管新生阻害剤ベバシズマブの効果
- 2011年, 日本整形外科学会雑誌, 85(6) (6)ヒト悪性線維性組織球腫細胞株におけるdecoy receptor3の抗アポトーシス作用に関する検討
- 2011年, 日本整形外科学会雑誌, 85(2) (2)SIRT1阻害による骨・軟部肉腫に対する細胞増殖抑制効果
- 2011年, 日本整形外科学会雑誌, 85(3) (3)遠位型頚椎症性筋萎縮症に対する保存的治療の成績-画像分類からみた病態の検討-
- 2011年, 日本整形外科学会雑誌, 85(6) (6)悪性線維性組織球腫細胞株に対する血管新生阻害剤ベバシズマブの効果
- 2011年, 日本整形外科学会雑誌, 85(8) (8)PGC-1α過剰発現によるミトコンドリアの増殖はMFHにおいてアポトーシスを促進する
- 2011年, 日本整形外科学会雑誌, 85(6) (6)Protein kinase D1は骨肉腫細胞においてMMP-2およびMMP-9の発現を制御して抗腫瘍効果を示す
- 2011年, 日本整形外科学会雑誌, 85(2) (2)SurvivinはMFHに対する治療の標的になりうる
- 2011年, 日本整形外科学会雑誌, 85(2) (2)骨・軟部腫瘍におけるprotein kinase D1の発現についての検討
- 2011年, 日本整形外科学会雑誌, 85(8) (8)ヒト悪性線維性組織球腫細胞株におけるDecoy receptor3の抗アポトーシス作用およびFas ligandによるアポトーシス誘導に関する検討
- 2011年, 日本整形外科学会雑誌, 85(6) (6)MFHに対するsurvivinを標的とした分子標的治療の可能性
- 2011年, 日本整形外科学会雑誌, 85(6) (6)ヒトMFH細胞株におけるprotein kinase C-deltaのアポトーシスへの影響についての検討
- 2011年, 日本整形外科学会雑誌, 85(8) (8)Protein Kinase C-deltaのヒトMFH細胞に対するアポトーシスへの影響についての検討
- 2010年06月, EJC SUPPLEMENTS, 8(5) (5), 70 - 70, 英語The effect of bevacizumab on intratumoural angiogenesis of malignant fibrous histiocytoma in animal model研究発表ペーパー・要旨（国際会議）
- 2010年, 日本整形外科学会雑誌, 84(8) (8)骨・軟部腫瘍におけるprotein kinase C-deltaの細胞増殖に関する役割についての検討
- 2010年, Journal of Spine Research, 1(4) (4)遠位型頚椎症性筋萎縮症の病態-保存的治療成績からの分析-
- 2010年, 日本整形外科学会雑誌, 84(6) (6)マウス悪性線維性組織球腫(MFH)モデルに対する血管新生阻害剤bevacizumabとdoxorubicinの併用療法の効果について
- 2010年, 日本整形外科学会雑誌, 84(6) (6)悪性線維性組織球腫細胞株に対する血管新生阻害剤bevacizumabの効果
- 2010年, 日本整形外科学会雑誌, 84(8) (8)マウス悪性線維性組織球腫(MFH)モデルに対する血管新生阻害剤ベバシズマブとドキソルビシンの併用療法の効果について
- 2010年, 日本整形外科学会雑誌, 84(8) (8)骨・軟部悪性腫瘍におけるSIRT1の発現とその阻害による抗腫瘍効果
- 2010年, 日本整形外科学会雑誌, 84(6) (6)骨・軟部腫瘍におけるProtein kinase D1の発現についての検討
- 2010年, 日本整形外科学会雑誌, 84(8) (8)骨・軟部腫瘍におけるprotein kinase D1の作用についての検討
- 2010年, 日本整形外科学会雑誌, 84(6) (6)骨・軟部腫瘍におけるprotein kinase C-deltaの細胞増殖に関する役割についての検討
- 2009年, 日本整形外科学会雑誌, 83(6) (6)マウス悪性線維性組織球腫(MFH)モデルにおける血管新生阻害剤bevacizumabの効果の検討
- 2009年, 日本整形外科学会雑誌, 83(6) (6)骨・軟部悪性腫瘍に対するsecond line化学療法としてのICE療法
- 2009年, 日本整形外科学会雑誌, 83(6) (6)悪性軟部腫瘍MFHにおけるスフィンゴシンキナーゼの発現および細胞増殖への検討
- 2009年, 日本整形外科学会雑誌, 83(8) (8)MFH細胞株に対する血管新生阻害剤bevacizumabの効果
- 2009年, 日本整形外科学会雑誌, 83(8) (8)マウス悪性線維性組織球腫(MFH)モデルにおける血管新生阻害剤bevacizumabの効果の検討
- 2009年, 日本整形外科学会雑誌, 83(6) (6)脱神経筋萎縮を伴った悪性末梢神経鞘腫瘍の2例
- 2008年, 日本職業・災害医学会会誌, 56手指運動麻痺を主訴とする頚椎症性筋萎縮症の治療成績:予後に影響を及ぼす画像所見の特徴についての検討
- 2008年, 日本脊椎脊髄病学会雑誌, 19(2) (2)手指運動麻痺を主訴とした頚椎症性筋萎縮症の病態
- 2008年, 日本脊椎脊髄病学会雑誌, 19(1) (1)腰椎後方除圧術における傍脊柱筋の損傷-棘突起から剥離することの意味-
- 2007年, 日本膝関節学会学術集会プログラム・抄録集, 32ndTKA後の止血対策としてのドレーンクランプ法におけるエピネフリンの有効性の検討
- 2006年, 中部日本整形外科災害外科学会雑誌, 49(4) (4)上腕三頭筋腱皮下断裂を生じた2例
- 2005年, 中部日本整形外科災害外科学会雑誌, 48徒手整復不能であったMTP関節背側脱臼の2例
- 2005年, 骨折, 27(Supplement) (Supplement)大腿骨か部・か上骨折に対する逆行性髄内釘の治療経験
- 2005年, 骨折, 27(Supplement) (Supplement)髄内釘を用いた上腕骨近位部骨折の治療経験
- 2003年, 中部日本整形外科災害外科学会雑誌, 46(6) (6)有痛性弾発肘の1例
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2027年03月31日小児骨肉腫における悪液質に伴う筋萎縮に対する抗酸化フラボノイドの効果
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2022年04月01日 - 2025年03月31日サルコペニアの骨格筋に対する経皮的炭酸ガス投与法の効果について
- 日本学術振興会, 科学研究費助成事業, 挑戦的研究(萌芽), 神戸大学, 2021年07月09日 - 2025年03月31日肉腫における液-液相分離と膜を持たない細胞内小器官に関する基礎研究2023年度（令和５年度）においては、骨肉腫細胞株MG63、KHOS、LM8、SaOS2中のストレス顆粒関連タンパク質(TIA-1、TIAR、G3BP1、G3BP2、CAPRIN-1、USP10)の 発現の有無をウェスタンブロットで再評価した。その結果、これらの細胞株で普通の培養下でストレス顆粒タンパク質が発現していることを再度確認した。また、ストレス顆粒関連タンパク質について、in vitroで各細胞株において蛍光免疫染色を行い共焦点レーザー顕微鏡で発現と局在を調べる。更にin vitroで低酸素環境下（酸素１％および5％）と通常酸素状態（酸素20％）のストレス顆粒タンパク質の遺伝子・タンパク質レベルでの発現の確認を開始した。 これらの細胞株のうちMG63にレトロウイルスを用いてOCT3/4、KLF4,SOX2を導入し、人工骨肉腫幹細胞MG-OKSを作製した。MG-OKSの網羅的遺伝子解析でMG-63に比し有意な発現上昇を認めた遺伝子から、がん関連の報告があるSPRR1Aに着目し、in vitroにてMG-OKSにSPRR1A選択的siRNAを導入し(siMG-OKS)、SPRR1Aの発現をqRT-PCRで確認し、細胞形態を位相差顕微鏡で観察した。細胞増殖能をWST-8 assayでMG-OKSとsiMG-OKSで比較検討した。結果は、qRT-PCRにてsiMG-OKSでSPRR1Aの発現低下を確認した。siMG-OKSはMG-OKSと比較し細胞増殖能が有意に低下していた。
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2021年04月01日 - 2024年03月31日人工骨肉腫幹細胞を用いた骨肉腫新規治療の開発本研究の目的は，我々が初めて作製に成功した人工骨肉腫幹細胞を用いて，骨肉腫の腫瘍発生・増生，再発・転移，治療抵抗性に関わる因子を解明することである．さらに，得られた結果を用いて臨床的に応用可能な治療標的を同定し，新規治療開発を行うことを目指す． これまでに，ヒト骨肉腫由来細胞株MG63にレトロウイルスベクターを用いてOCT3/4，KLF4，SOX2の3遺伝子を導入して作製した人工骨肉腫幹細胞MG-OKSと，同様の方法でGFPを導入して作製したコントロール細胞MG-GFPを用いて，各細胞における幹細胞関連マーカー，細胞増殖能，細胞遊走能，スフェア形成能等幹細胞特性の検討を行ったところ，MG-OKSでは幹細胞関連マーカーの発現上昇，細胞増殖能低下，細胞遊走能上昇，スフェア形成能上昇がみられ，幹細胞特性を有していることを明らかとした．さらに人工骨肉腫細胞MG-OKS，コントロール細胞MG-GFPおよび親細胞株MG-63の網羅的遺伝子解析をMicroarrayで行ったところ，MG-OKSにおいてMG-GFPおよびMG-63よりも10倍以上発現上昇をみとめた遺伝子が200個以上検出された．同遺伝子群の機能解析をGene ontologyを用いて行ったところ，悪性腫瘍との関連が報告されている遺伝子群の発現上昇が確認された．これら遺伝子群からSPRR1A遺伝子に着目し，治療標的あるいは腫瘍マーカーとして応用可能かについて現在様々な検討を行っている．
- 日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 2021年03月01日 - 2023年03月31日細胞移植を必要としない骨再生治療の創出-新規開発骨誘導型コラーゲンを用いた挑戦
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2018年04月01日 - 2021年03月31日iPS細胞作製技術を用いた人工骨肉腫幹細胞の樹立と機能解明希少がんである骨肉腫細胞からiPS細胞作製技術を応用して幹細胞の性質を併せ持つ骨肉腫幹細胞を作製し，その性質について検討を行った． 骨肉腫細胞株MG-63にOCT3/4・KLF4・SOX2を遺伝子導入することで，骨肉腫とがん幹細胞の特性を持つ細胞の作製に成功した．同細胞は，幹細胞マーカーの発現上昇、細胞増殖能低下、薬剤耐性能・細胞遊走能・骨形成能の増強を認め，In vivoでの腫瘍形成能増強と腫瘍組織内の悪性度上昇を認めた。本研究によって，骨肉腫細胞に特定因子を導入することでがん幹細胞の特性を獲得し得ることが明らかとなり，骨肉腫の新たな病態理解や治療標的分子の同定，新規治療開発が期待される．
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2017年04月01日 - 2021年03月31日転移性骨腫瘍の骨リモデリングに対する炭酸ガス療法の効果について乳癌骨転移モデルマウスを作成し、経皮的炭酸ガス治療群とコントロール群で骨転移部の骨形態学的、質的評価を行い、摘出した組織で病理組織学的、分子生物学的に低酸素環境の評価、破骨細胞による骨吸収の評価を行った。経皮的炭酸ガス治療群では腫瘍サイズ、マイクロCT画像において腫瘍の増大が抑制されていた。病理組織学的には、治療群の脛骨病巣部でHIF-1αの発現が抑制され、TRAP陽性細胞数が減少していた。また、RANKL, IL-1β, IL-6, IL-8の発現抑制を認めたことより、経皮的炭酸ガス治療が乳癌骨転移の低酸素環境を改善させ、破骨細胞の分化誘導を抑制し骨破壊を抑制した可能性が示唆された。
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2014年04月01日 - 2019年03月31日悪性骨軟部腫瘍に対する経皮二酸化炭素療法を応用した新規化学療法の開発に関する研究経皮二酸化炭素療法は、MFH/UPS・骨肉腫細胞皮下移植、さらに、乳がん細胞脛骨移植動物モデルにおいて、重大な副作用なく抗腫瘍効果および骨破壊抑制効果を示した。その作用機序は、ミトコンドリア系アポトーシスの活性化を介していることが示唆された。また、HIF-1α, MMP-2および9の発現抑制を介して、肺転移の抑制効果も認められた。さらに、化学療法（ドキソルビシン）の併用効果も認められ、ミトコンドリア系アポトーシスの相乗的な活性化による抗腫瘍効果の機序が示唆された。一方、本療法の臨床試験において、目立った副作用は認めなかった。よって本治療法は、悪性腫瘍に対する新たな治療法となりうる可能性がある。
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2014年04月01日 - 2017年03月31日肉腫幹細胞に対する炭酸ガス経皮投与を用いた新規治療の開拓骨軟部肉腫に対するより強力な新規治療法の確立のための基礎的研究として，腫瘍悪性化・増生の根幹となる未分化能（肉腫幹細胞）と関連する因子としてミトコンドリア機能に着目し，我々が開発した炭酸ガス経皮投与による低酸素環境改善の有効性について検討した． 骨軟部肉腫において未分化能の指標であるiPS関連因子の発現が高いこと，ミトコンドリア機能が低下していることが確認され，いずれも低酸素環境によってより増強することを明らかにした．さらに炭酸ガス経皮投与による低酸素環境の改善によって未分化能の低下，ミトコンドリア機能の改善を生じることも確認され，骨軟部肉腫に対する新規治療法となり得ることが期待された．